HealthTech, Digital Health, MedTech IPO predictions 2026 2026 Strategic Outlook: The Industrialisation of HealthTech, MedTech and Digital Health Capital Markets As the global healthcare sector approaches the 2026 fiscal year, the capital markets are poised for a definitive structural transformation. Following a tumultuous half-decade characterized by the exuberant highs of the Zero Interest Rate Policy (ZIRP) era and the subsequent liquidity crunch of 2022–2024, the IPO landscape has entered a phase of "Rational Exuberance." This new paradigm is defined not by the speculative fervour that drove the 2020–2021 vintage, but by a disciplined adherence to unit economics, clinical validation, and infrastructural durability. The analysis indicates that 2026 will function as a "clearing event" for the digital health and medtech sectors.The bifurcation of the market is no longer a forecast but a realised operational reality. Capital is concentrating efficiently around assets that demonstrate profitable scalability, while "point solutions" and growth-at-all-costs narratives are being aggressively discounted or forced into consolidation. The IPO pipeline for 2026 is robust, yet selectively permeable, favouring companies that have successfully transitioned from venture-subsidised experiments to industrialised platforms capable of delivering measurable return on investment (ROI) to payers, providers, and patients alike. Current market intelligence suggests a distinct shift in underwriting criteria. Public market investors, burned by the post-IPO performance of the previous cohort, are prioritizing "infrastructure-grade" businesses, those embedded deeply into the clinical or financial workflows of the healthcare system, over consumer-facing novelties. This trend is exemplified by the anticipated mega-listings of Zelis Healthcare and Medtronic MiniMed, as well as the strategic positioning of AI-native platforms like Abridge and Commure which promise not just incremental efficiency, but fundamental labor substitution. Furthermore, the convergence of high-performance computing with biological discovery, a sector increasingly termed "TechBio", has matured to a point where capital markets are preparing to underwrite platform risks, provided those platforms are supported by tangible clinical assets. The prospective listings of Xaira Therapeutics, Insitro and Generate:Biomedicines represent a test case for this thesis, challenging the traditional binary outcomes of biotech investing with the promise of industrialised drug discovery. This report provides a multi-dimensional analysis of the 2026 IPO outlook. It dissects the macroeconomic levers, evaluates sector-specific dynamics and profiles the Tier-1 candidates that will define the vintage. By integrating granular financial data, strategic sentiment analysis and regulatory context, we aim to provide a definitive roadmap for institutional investors navigating this resurgent asset class. Macroeconomic & Regulatory Architecture (2025–2026) The venture capital ecosystem, the primary feeder for the IPO pipeline, is undergoing a radical structural consolidation that will directly influence the quality and quantity of 2026 listings. The "middle market" of venture capital, firms managing between $150 Million and $500 Million is collapsing. Limited Partners (LPs) are bifurcating their allocations, directing approximately 80% of capital to "Brand Name" mega-funds that effectively offer an index of the innovation economy and the remaining 20% to hyper-specialised "Satellite" funds capable of generating alpha through deep domain expertise. This consolidation forces mid-stage healthtech companies into a binary outcome: achieve the scale and metrics required by mega-funds and public markets, or face consolidation. Consequently, the 2026 IPO class will likely be leaner in volume but significantly higher in average quality compared to the 2021 cohort. The "Series B/C cliff" has successfully filtered out non-viable business models, leaving a backlog of mature, late-stage companies that have spent the last three years optimising operations rather than chasing vanity metrics. Furthermore, the emergence of secondary funds as a permanent fixture of the liquidity landscape has altered the IPO timeline. With secondary transaction volumes projected to exceed $210 Billion in 2025, founders and early employees have found liquidity avenues outside of the public markets. This reduces the pressure to IPO prematurely for liquidity purposes, allowing companies like Sword Health and Commure to time their debuts based on strategic optimality rather than employee retention pressures. Interest Rate Stabilisation and Valuation Parity The stabilisation of global interest rates in late 2025 has provided the necessary bedrock for valuing long-duration assets common in medtech and biotechnology. As the cost of capital becomes predictable, equity risk premiums are normalising, reopening the window for capital-intensive businesses. A critical secondary effect of this stabilization is the closing of the valuation arbitrage gap between European and US healthtech assets. Historically, European companies traded at a discount, but aggressive scouting by US Private Equity and Growth Equity firms is driving convergence. By 2026, top-tier European healthtech companies are expected to command valuations at parity with their US counterparts, necessitating the "Delaware Flip", a legal restructuring to US domiciles, as a prerequisite for accessing deep US capital pools via IPOs. The Policy Headwinds: Pricing, Privacy and Antitrust While the financial markets show signs of thawing, the regulatory environment presents a complex matrix of headwinds and tailwinds that will shape the 2026 narrative. Federal Drug Pricing Controls: In 2026, the US federal government will, for the first time, implement negotiated prices for 10 high-spend Medicare Part D drugs under the Inflation Reduction Act. This structural change in biopharma economics will exert downward pressure on the terminal value of single-asset biotech IPOs. Conversely, it creates a massive tailwind for TechBio platforms that promise to reduce the cost and time of drug development, positioning companies like Insitro and Recursion as essential efficiency partners for big pharma. Antitrust and M&A Scrutiny: The Federal Trade Commission (FTC) and Department of Justice (DOJ) have intensified scrutiny on healthcare consolidation, particularly vertical integration by payers (e.g., UnitedHealth/Optum) and hospital systems. This regulatory "chill" on M&A may inadvertently strengthen the IPO pipeline by removing the trade sale exit route for mid-sized companies, forcing them to seek public capital to remain independent. Reimbursement Innovation: The introduction of new CMS codes for digital mental health treatment devices and AI-driven cardiovascular diagnostics in 2025 has been a watershed moment. These codes transition digital therapeutics from "experimental" to "reimbursable," validating the revenue models of companies like HeartFlow and Pear Therapeutics (or its successors). For 2026 candidates, securing distinct CPT codes or inclusion in value-based care bundles is now a primary diligence item for underwriters. The Private Equity Resurgence Private Equity sponsors are positioned to play an expanded, aggressive role in 2026 deal formation. Having accumulated significant dry powder and a portfolio of mature assets during the deal hiatus, PE firms are preparing for a cycle of exits. The trend is shifting from financial engineering to operational value creation. Sponsors are engaging in "build-to-buy" constructs and platform consolidation to create assets with the scale necessary for public markets. The anticipated IPO of Zelis Healthcare, backed by Bain Capital, exemplifies this trend, a massive, profitable, PE-assembled platform entering the public market as a category leader. The Anchor Tenants: Large Cap IPO Candidates The 2026 IPO vintage will be anchored by a select group of "Mega-Cap" listings, companies with multi-billion dollar valuations, proven profitability or clear paths to it, and dominant market positions. These listings will set the tone for investor sentiment and establish the valuation multiples for the broader sector. Zelis Healthcare: The Defensive Growth Juggernaut Sector: FinTech / Healthcare Payments Anticipated Valuation: ~$17 Billion Status: S-1 Confidential Filing (Target Q1 2026) Sponsors: Bain Capital, Parthenon Capital Underwriters: Goldman Sachs, JPMorgan Strategic Analysis: Zelis Healthcare stands as the premier "defensive growth" asset of the 2026 cycle. Operating at the intersection of healthcare and financial technology, Zelis addresses one of the most persistent inefficiencies in the US healthcare system: the fragmentation of payments between payers, providers and consumers. The company’s platform modernises claim management and payment processing, reducing administrative waste and fraud. Financial Fortress: Unlike the speculative digital health listings of 2021, Zelis enters the market with a fortress balance sheet. Reports indicate the company generates nearly $1 billion in EBITDA, a metric that immediately places it in the top decile of healthtech assets. This profitability profile is highly attractive to institutional investors seeking exposure to healthcare innovation without the cash-burn risk associated with earlier-stage ventures. The valuation target of $17 Billion is supported by recent minority stake sales to sovereign wealth funds like Mubadala, establishing a firm valuation floor. Market Positioning: Zelis functions as a critical infrastructure layer. By integrating with hundreds of payers and millions of providers, it has built a deep competitive moat. Its revenue model is largely transactional and recurring, providing visibility and resilience against macroeconomic downturns. The company’s growth strategy involves expanding its "payment integrity" solutions—using AI to detect errors and fraud before payments are released—and moving upstream into price transparency tools, capitalizing on the regulatory tailwinds of the No Surprises Act. Risks and Considerations: The primary risk for Zelis lies in the regulatory complexity of healthcare payments. The transparency rules that drive demand for its compliance solutions also expose it to scrutiny regarding its own fee structures. Additionally, as a centralised node for financial data, cybersecurity is an existential risk; a breach could be catastrophic for trust. However, its scale allows for massive investment in security infrastructure that smaller competitors cannot match. Medtronic MiniMed: The Pure-Play Diabetes Spin-Off Sector: MedTech / Diabetes Management Status: Form S-1 Filed (December 2025) Ticker: NASDAQ: MMED Revenue: ~$2.7 Billion (FY 2025) Underwriters: Goldman Sachs, BofA Securities, Citigroup, Morgan Stanley Strategic Analysis: Medtronic’s decision to spin off its Diabetes operating unit into a standalone public company, MiniMed Group, creates an immediate heavyweight competitor to Dexcom and Abbott Laboratories. This transaction unlocks value by separating the high-growth diabetes business from the conglomerate discount applied to Medtronic’s broader portfolio. Technological Renaissance: Historically, Medtronic struggled with product cycles in diabetes, falling behind Dexcom in sensor technology. However, the spin-off coincides with a product renaissance. The MiniMed 780G system, featuring the proprietary SmartGuard algorithm, has closed the performance gap, offering automated insulin delivery (AID) that adjusts basal rates every five minutes. Crucially, the system’s newly cleared compatibility with Abbott’s Freestyle Libre sensors signals a strategic pivot from a "walled garden" approach to an interoperable ecosystem, significantly expanding the addressable market. Financial Profile: MiniMed generated $1.5 Billion in revenue for the six months ended October 24, 2025, implying a roughly $3 Billion annual run rate.9 While the unit reported a net loss of $21 Million for that period, it generated $128 Million in Adjusted EBITDA, demonstrating strong underlying cash generation capabilities. The geographic diversity of its revenue, 70% derived from international markets, provides a hedge against US reimbursement pressures and aligns with the global epidemic of diabetes. IPO Implications: For investors, MiniMed offers a "pure play" on the diabetes tech super-cycle, driven by the global adoption of CGMs and pumps. The separation allows MiniMed to allocate capital more aggressively toward R&D and direct-to-consumer marketing, unencumbered by Medtronic’s corporate overhead. Freenome: The SPAC Reinvention Sector: Diagnostics / Liquid Biopsy Transaction Value: ~$1.1 Billion Enterprise Value Structure: Merger with Perceptive Capital Solutions Corp (NASDAQ: PCSC) Timeline: H1 2026 Completion Strategic Analysis: In a market that has largely shunned Special Purpose Acquisition Companies (SPACs), Freenome’s definitive agreement to merge with Perceptive Capital Solutions Corp represents a maturing of the vehicle. This is not a speculative grab for cash; it is a structured financing event backed by a high-quality PIPE (Private Investment in Public Equity) led by sector specialists Perceptive Advisors and RA Capital. The Clinical Imperative: Freenome operates in the high-stakes arena of multiomics early cancer detection. Its flagship focus is colorectal cancer (CRC), a market currently dominated by Exact Sciences (Cologuard) and Guardant Health. Freenome’s approach differs by integrating genomic, proteomic and transcriptomic data to improve sensitivity and specificity for early-stage adenomas. The capital raised, approximately $330 Million ($90M trust + $240M PIPE), is explicitly earmarked for the 2026 commercial launch of its blood-based CRC test. Valuation Discipline: The deal values Freenome at an enterprise value of $1.1 Billion, a figure that appears conservative relative to the total capital raised in the private markets (over $1.3 Billion). This "down round" dynamic reflects the public market’s compression of diagnostic multiples and the rigorous pricing discipline enforced by the PIPE investors. For public investors, this entry price mitigates valuation risk and offers significant upside if the clinical launch meets adoption targets. Commercial Moat: Freenome has forged strategic partnerships with Roche and Exact Sciences, creating a unique industry structure where potential competitors are also stakeholders and commercial partners. This validates the technology and provides immediate distribution leverage upon FDA approval. The Digital Health Industrialisation: Platforms at Scale The 2026 cohort of digital health companies represents the survivors of the "Great Clearing." These organisations have proven that digital health is not merely a Zoom call with a doctor, but a scalable industrial process that combines human expertise with AI efficiency to deliver superior clinical outcomes at lower costs. Post IPO Performance as a Leading Indicator The appetite for 2026 digital health IPOs is directly correlated with the performance of the "Class of 2025," specifically Hinge Health and Omada Health. Their post-listing trajectories serve as the benchmark for upcoming candidates. Hinge Health (NYSE: HNGE): Market Validation: Since its May 2025 IPO priced at $32, Hinge Health shares have appreciated approximately 63%, trading near $47 by late 2025. Execution: The company reported Q2 2025 revenue of $139.1 million, a 55% year-over-year increase, smashing analyst expectations. More impressively, non-GAAP gross margins expanded to 83%, a figure typical of pure SaaS companies rather than tech-enabled services. The "Hybrid" Moat: Hinge's model, combining wearable sensors, computer vision, and human PTs has reduced human labor hours by 95% compared to traditional therapy. This unit economic leverage is the primary driver of its valuation premium. Omada Health (NASDAQ: OMDA): Profitability Milestone: Omada achieved a critical psychological and financial milestone in Q3 2025 by posting positive Adjusted EBITDA of $2 million for the first time. GLP-1 Synergy: Rather than being displaced by GLP-1 weight loss drugs, Omada successfully pivoted to become a companion platform. Its "GLP-1 Care Track" manages the adherence and lifestyle modification required for these drugs, proving that digital health can be symbiotic with pharma. These successes have signaled to investors that the digital health business model is viable, durable, and capable of generating free cash flow. This sets the stage for the next wave of platforms. Sword Health: The Strategic Delay Sector: Digital MSK / AI Care Valuation: $4 Billion (June 2025) Status: Private; CEO guiding to 2028 IPO Strategic Analysis: Sword Health provides the counter-narrative to the rush for liquidity. In June 2025, the company raised $40 Million at a $4 Billion valuation specifically to delay its IPO. CEO Virgilio Bento has publicly stated a target of 2028 for a listing, citing a desire to prove the efficacy of the company's new "Phoenix" AI agent across multiple clinical verticals before exposing the company to quarterly public scrutiny. The AI Agent Thesis: Sword is betting its future on "Phoenix," an autonomous AI care specialist capable of holding voice conversations and adjusting treatment plans in real-time. By moving from human-in-the-loop to AI-first, Sword aims to push gross margins even higher than Hinge’s 83%. The company is currently cash-flow positive with a revenue run rate of $240 Million. While the CEO guides to 2028, market observers note that secondary liquidity pressures and the robust performance of its peer Hinge Health could accelerate this timeline to late 2026 if market conditions are optimal. Noom: From App to Healthcare Provider Sector: Metabolic Health / Weight Management Status: IPO Pipeline (Rumoured 2026) Key Catalyst: Highmark Health Partnership Strategic Analysis: Noom has undergone a profound transformation from a direct-to-consumer (DTC) weight loss app to a clinically integrated enterprise healthcare provider. The catalyst for this shift is the GLP-1 wave. Recognising that behavioural coaching alone cannot compete with the efficacy of Ozempic and Wegovy, Noom launched "Noom Med," a clinical service that prescribes and manages these medications. The Payer Pivot: The critical unlock for a 2026 IPO is the recently announced partnership with Highmark Health, effective January 1, 2026. This deal grants nearly 2 Million members access to Noom’s weight management and diabetes prevention programs as a covered benefit. This transition from volatile consumer subscription revenue to recurring, contract-based payer revenue fundamentally changes the quality of Noom's earnings, making it a prime candidate for an institutional offering. Maven Clinic: The ESG & Economy of Care Play Sector: Women’s and Family Health Valuation: $1.7 Billion Status: IPO Ready; Series F (Aug 2024) Strategic Analysis: Maven Clinic has consolidated the fragmented women’s health market, offering a comprehensive platform spanning fertility, maternity, paediatrics, and menopause. With $125 Million in fresh Series F capital led by StepStone Group, Maven is deepening its "Maven Managed Benefit" platform, which administers fertility benefits for employers. Investment Thesis: Maven appeals to two distinct investor mandates: ROI: By reducing C-section rates and NICU stays, Maven delivers hard-dollar savings to self-insured employers. Social Impact: As reproductive rights and health equity remain central societal issues, Maven represents a rare high-growth asset with intrinsic ESG value. The hiring of public-company-ready finance leadership suggests the company is preparing its internal controls for a 2026 debut. The Frontier: TechBio and AI Infrastructure The intersection of biology and machine learning, often termed TechBio, is generating the highest private market valuations. However, these companies face a higher burden of proof: they must demonstrate that their algorithms actually produce better drugs, faster. Xaira Therapeutics: The Billion-Dollar Bet Sector: AI Drug Discovery Funding: $1 Billion Launch (2024) Backers: ARCH Venture Partners, Foresite Capital Strategic Analysis: Xaira represents the "Industrialised R&D" thesis. Launched with over $1 Billion in committed capital, the company is building a "virtual cell" simulation using massive datasets derived from perturb-seq technologies. The goal is to simulate drug interactions in silico before ever touching a wet lab. While 2026 might be early for a company founded in 2024, the sheer scale of capital deployment and the pedigree of its backers (Robert Nelsen of ARCH) suggest that a public listing could be used to fund massive Phase I/II clinical trials if the platform yields candidates quickly. Insitro: The Machine Learning Pioneer Sector: TechBio Valuation: $2.5 Billion Status: Late-Stage Private Strategic Analysis: Led by machine learning pioneer Daphne Koller, Insitro uses induced pluripotent stem cells (iPSCs) to create disease models that generate massive, high-fidelity biological datasets. These datasets train ML models to identify targets that are invisible to traditional screening. Unlike companies that rely on public data, Insitro’s moat is its proprietary data generation factory. With partnerships with Gilead and Bristol Myers Squibb, and a pipeline approaching clinical readouts, Insitro is a prime candidate for a 2026 IPO to fund independent drug development. Abridge and Commure: The Ambient Intelligence Layer Sector: Healthcare AI / Documentation Valuation: Abridge ($5.3Bn), Commure ($6Bn) Strategic Analysis: These companies are fighting to own the "ambient layer" of healthcare—the AI that listens to doctor-patient conversations and automatically generates clinical notes and billing codes. Abridge: Raised a Series E in mid-2025 at a $5.3 Billion valuation. Its "Contextual Reasoning Engine" goes beyond transcription to structure data specifically for the Revenue Cycle Management (RCM) process, directly impacting hospital cash flow. Commure: Aggregated multiple point solutions (Augmedix, Athelas) into a "Healthcare OS." With $200 Million in annual recurring revenue (ARR) and a growth rate doubling annually, CEO Tanay Tandon has explicitly signalled "IPO readiness" within a two-year window from mid-2025, placing the target squarely in late 2026. The risk for this sector is commoditisation by foundation models (e.g., GPT-5). To survive, these companies must prove that their integration into the EHR (Epic/Cerner) and their proprietary RCM workflows provide a moat that a generic LLM cannot cross. Emerging Opportunities & Global Markets Regional Analysis Asia-Pacific: The Asian markets are active, with Insilico Medicine filing for a Hong Kong IPO to raise ~$300 Million. This listing serves as a bellwether for AI drug discovery valuations globally. In India, Practo Technologies is exploring a 2026 IPO, capitalising on the digitisation of the Indian healthcare consumer and relocating its domicile from Singapore to India to facilitate the listing. Europe: The European healthtech ecosystem is maturing, with companies like Doctolib (France) and Sword Health (Portugal/US) leading the charge. The trend is decisively towards US listings (the "Delaware Flip") to access deeper liquidity and higher multiples, with European exchanges struggling to retain their tech champions. Medtech Innovations Kestra Medical Technologies: A dark horse for 2026. Specializing in wearable cardioverter defibrillators (WCDs), Kestra reported 53% revenue growth in Q2 2025. While currently loss-making, its gross margin expansion (crossing 50%) and high-growth profile make it an attractive acquisition target or IPO candidate for growth-focused funds. HistoSonics: Pioneering "histotripsy", the use of sound waves to mechanically destroy tumours. With a recent $250 Million raise and FDA clearance for liver tumours, the company is expanding into kidney and pancreatic indications. An IPO in 2026 would fund global commercialisation and the build-out of a dedicated sales force. Conclusions and Strategic Outlook The 2026 healthcare IPO vintage will be defined by Quality over Quantity. The era of the "concept stock" in digital health is over. The market has shifted to a "show me" regime where clinical evidence, unit economics and infrastructural relevance are the prerequisites for public capital. Key Predictions: The Return of the Mega-Deal: Zelis Healthcare and Medtronic MiniMed will be the largest listings of the year, validating the appetite for profitable, large-scale healthcare assets. AI as Utility: Companies like HeartFlow, Abridge, and Commure will succeed by proving that AI is not a feature, but a utility that lowers the cost of care delivery. The SPAC Redemption: Freenome will demonstrate that the SPAC vehicle, when used with rigorous PIPE backing and realistic valuations, remains a viable path for high-science capital-intensive businesses. The GLP-1 Effect: Companies that successfully integrate with the GLP-1 ecosystem (like Omada and Noom) will be rewarded; those that ignore it will face existential headwinds. The 2026 Tier-1 IPO Watchlist Company Sector Status Est. Valuation Key Differentiator Zelis Healthcare FinTech S-1 Filed ~$17B $1B EBITDA; Defensive payments infrastructure Medtronic MiniMed MedTech S-1 Filed N/A (Spinoff) Pure-play diabetes tech; $2.7B Revenue Freenome Diagnostics Merger Agreed $1.1B Multiomics CRC screening; Roche Partnership Commure Health AI IPO Ready $6B $200M ARR; "Healthcare OS" Platform Sword Health Digital MSK Private $4B "Phoenix" AI Agent; Cash flow positive Maven Clinic FemTech Private $1.7B Fertility benefits dominance; ESG appeal Abridge AI Scribe Private $5.3B RCM-integrated ambient documentation Insitro TechBio Private $2.5B iPSC-driven data generation factory Kestra Medical MedTech S-1 Filed Small Cap 53% Growth; Wearable Cardiac Tech HistoSonics MedTech Private $2.25B Non-invasive tumor destruction (Histotripsy) For investors, 2026 offers a window to access the "industrialised" layer of healthcare innovation. The risks have shifted from "will the technology work?" to "can the business model scale profitably?", a challenge that the Tier-1 candidates profiled in this report appear well-equipped to meet. Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events October 2025 Healthcare Summit 2025, London, UK – Chairing the HealthTech M&A Panel Healthcare Summit 2025, London, UK – Chairing the HealthTech Deal Structuring Panel NHS Clinical Entrepreneur Conference, Belfast, Northern Ireland Global Health Exhibition 2025, Riyadh, Saudi Arabia – Chairing the HealthTech M&A Panel November 2025 HealthTech X Summit, London, UK – Chairing the “HealthTech predictions for 2026” Panel MedTech Europe 2025, Valletta, Malta- Speaker on the "Startups, Corporates & Hospitals: How to Build Meaningful MedTech Partnerships" panel MedTech Europe 2025, Valletta, Malta- Judge for the MedTech StartUp Pitch Awards Leaders in Health Summit 2025 December 2025 HealthTech Forward 2025, Barcelona, Spain – Moderating the Health Data Under Attack” Panel Healthcare Club, IESE Business School, Barcelona, Spain HealthInvestor Power List Awards 2025, London, UK – Judging Panel Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

The Rise of the 'Founder Banker' advising European HealthTech and MedTech Executive Summary The European financial advisory landscape for Healthcare Technology (HealthTech) and Medical Technology (MedTech) is currently navigating a period of profound structural transformation. For the better part of three decades, the provision of merger and acquisition (M&A) advisory services was the exclusive domain of career financiers, individuals whose expertise lay in financial engineering, balance sheet restructuring, and capital markets access, but who frequently lacked direct operational experience in the industries they served. As the European digital health sector matures, transitioning from a nascent collection of startups into a critical component of national infrastructure, a new paradigm is emerging: the rise of the "Founder Banker." This report provides an analysis of this new generation of advisors. These are individuals who have successfully built, scaled and exited their own ventures before transitioning into advisory roles. They bring a distinct value proposition characterised by "operational empathy," deep technical fluency and an ability to bridge the widening gap between the metrics of the digital economy (SaaS) and the regulatory realities of healthcare (clinical validation). The analysis reveals a marked bifurcation in the market structure. While "Mega-Cap Generalists" like Goldman Sachs and J.P. Morgan continue to dominate multi-billion dollar transformative deals, increasingly bolstering their ranks with medical doctors (MDs) to gain scientific credibility, a vibrant ecosystem of "Specialist Boutiques" has emerged to serve the mid-market. Firms such as Nelson Advisors in the UK, Clipperton in France, and ConAlliance in the DACH region are redefining how value is articulated in a market constrained by high interest rates and regulatory headwinds like the EU AI Act. This report outlines the biographies, strategies and market impact of these founder led firms. It explores how their operational DNA influences deal structuring, valuation methodologies and the navigation of complex regulatory frameworks. Furthermore, it posits that the "Founder Banker" model is not merely a niche trend but a necessary evolution in an industry where the complexity of the underlying assets, AI algorithms, digital therapeutics and interconnected care platforms, exceeds the analytical capabilities of generalist finance. The Macro-Strategic Context of the Advisory Shift The Dissolution of the Generalist Model The genesis of the founder-led advisory movement lies in a fundamental inefficiency within the traditional investment banking model, often referred to as the "Translation Gap." Historically, healthcare banking and technology banking operated as distinct, hermetically sealed silos. Healthcare bankers were trained to understand reimbursement codes, clinical trial phases, and the slow, capital-intensive path to regulatory approval. Conversely, technology bankers were conditioned to value assets based on software-as-a-service (SaaS) metrics: Customer Acquisition Cost (CAC), Lifetime Value (LTV), Annual Recurring Revenue (ARR), and churn rates. The emergence of Digital Health, where software intersects directly with patient care, created a class of assets that fit neither category neatly. A digital therapeutic company might possess the recurring revenue model of a software firm but carry the regulatory burden and clinical risk profile of a pharmaceutical company. Traditional healthcare bankers often undervalued the software scalability of these assets, while tech bankers frequently underestimated the regulatory "moats" and clinical risks involved. This translation gap created a market failure where high-quality assets were either misunderstood by buyers or undervalued during exits. The "New Generation" of advisors emerged specifically to fill this void. These individuals, often former founders themselves, possess the bilingual fluency required to speak "SaaS" to technology investors and "Clinical Outcomes" to healthcare incumbents. The Convergence of "Tech" and "Bio" The acceleration of this trend is driven by the increasing convergence of technology and biology, often termed "TechBio." As artificial intelligence (AI) becomes central to drug discovery, diagnostics and patient management, the diligence required for M&A has shifted from purely financial to deeply technical and scientific. The ability to distinguish between a commoditised "AI wrapper" and a defensible, proprietary algorithm requires a level of technical literacy that generalist bankers rarely possess. The market has simultaneously transitioned from a "growth at all costs" mindset, prevalent during the Zero Interest Rate Policy (ZIRP) era, to a disciplined "flight to quality" where profitability, unit economics, and proven clinical utility are paramount. In this disciplined environment, the advisor's role transitions from a mere facilitator of transactions to a "strategic architect" of corporate destiny. Founder bankers, having navigated these cycles as operators, are uniquely positioned to guide companies through the complex "build, buy, partner, or sell" decision matrix, offering advice that extends far beyond the transaction itself. The Four Archetypes of Modern Advisory The current advisory landscape in Europe can be categorised into four distinct archetypes, each serving a specific segment of the market and offering a different value proposition regarding founder involvement: Advisory Archetype Key Characteristics Founder/Operator Presence Representative Firms The Mega-Cap Generalists Global balance sheet, IPO execution, cross-border scale. Medical/Scientific : Hiring MDs (e.g., Philippe Gallone) for scientific credibility rather than entrepreneurial experience. Goldman Sachs, J.P. Morgan, Morgan Stanley The Specialist Boutiques Niche expertise, founder-centric, operational empathy, "Founders for Founders." High (Entrepreneurial): Led by ex-founders who have built and exited their own ventures. Nelson Advisors, ConAlliance, WG Partners, Think.Health The Tech-Centric Scale Players "Digital Economy" lens, software metrics focus, cross-border reach. Moderate: Often tech-focused career bankers with deep venture networks and some operator partners. Arma Partners, GP Bullhound, Clipperton The Hybrid Investor-Advisors Combine VC investing with strategic advisory; "Skin in the game." Very High: Active investors who also advise, bringing portfolio management experience. Think.Health , HGM Advisory The "Founders for Founders" Model – The UK Ecosystem The United Kingdom, serving as a primary hub for European digital health innovation, has birthed a specific breed of advisory firm that explicitly markets itself on the entrepreneurial pedigree of its partners. This is not merely a branding exercise but a fundamental rethinking of the advisory business model. Nelson Advisors: The Pure Play Operator Model Among the boutique advisors serving the European market, Nelson Advisors stands out for its distinct "Founders for Founders" operational model. Unlike traditional investment banks staffed by career financiers who have moved linearly from analyst to managing director, Nelson Advisors is led by individuals who have successfully built, scaled and exited their own HealthTech ventures. Key Leadership and Operational Pedigree The firm's credibility is anchored in the track records of its founding partners, Lloyd Price and Paul Hemings, whose combined experience bridges the gap between high-level corporate finance and the gritty reality of startup execution. Lloyd Price (Co-Founder & Partner): Price represents the convergence of consumer internet and deep healthtech. His background spans over 25 years, including early roles at consumer internet giants Yahoo and Kelkoo. Crucially, he founded Zesty, a patient engagement platform. Zesty was a pioneering digital health venture that navigated the complex procurement landscape of the UK's National Health Service (NHS) before being acquired by Induction Healthcare. This trajectory is critical: Price understands the consumer engagement metrics (Daily Active Users, Monthly Active Users) that technology buyers value, but his experience with Zesty gives him the "scars" of integrating with hospital legacy systems and navigating clinical pathways. He actively leverages this status as a "Health Executive in Residence" at UCL Global Business School for Health, bridging academia, industry, and finance. Paul Hemings (Co-Founder & Partner): Hemings offers a complementary profile, blending high-level investment banking with entrepreneurial risk-taking. His corporate finance background includes tenure at Credit Suisse and Invesco, where he executed over $50 billion in M&A and equity transactions. However, unlike a typical banker, he left the safety of the bulge bracket to co-found Neutrally, a metabolic health venture focusing on chronic lifestyle disease. This dual background allows him to structure complex cross-border financial deals while retaining the credibility of a founder who has "been in the arena." His expertise is particularly pivotal in the "TechBio" and longevity sectors, where the science is dense and the capital requirements are high. Strategic Differentiation: "Operational Empathy" The firm's strategy is predicated on "Operational Empathy." In the lower mid-market ($25M - $250M), where Nelson Advisors primarily operates, founders are often selling their life's work. The psychological aspect of the transaction is as significant as the financial one. A banker who has sold their own company can navigate the emotional volatility of a founder-exit in a way that a career financier cannot. Their service offering extends beyond simple M&A execution to a broader "Build, Buy, Partner, Sell" strategy. This implies a longer-term engagement where the firm advises on growth and operational scaling before a transaction is contemplated, effectively acting as an outsourced corporate development team. This is particularly relevant in the current "distressed" or "consolidated" market, where they advise buy-side clients on "roll-up" strategies to combat "point solution fatigue" among hospital CIOs. WG Partners and the Life Sciences Convergence While Nelson Advisors focuses on Digital Health and Health IT, WG Partners represents the life sciences side of the UK boutique ecosystem. They specialise in capital raising and advisory for small-to-mid-cap healthcare companies. Their relevance to the "founder banker" theme lies in their deep integration with the venture capital (VC) community. They serve as a bridge for biotech and medtech firms that are too small for the bulge bracket but require sophisticated equity storytelling for public markets or cross-border trade sales. The distinction here is crucial: Nelson Advisors leans towards HealthTech (software/data), while WG Partners leans towards Life Sciences (biotech/devices). However, as these fields converge, exemplified by AI in drug discovery, the overlap between these advisory models increases, creating a demand for advisors who can navigate both worlds. The DACH Ecosystem – Industrial Roots and Hybrid Models The DACH region (Germany, Austria, Switzerland) presents a different advisory landscape, heavily influenced by its strong industrial MedTech base (Mittelstand) and a conservative, yet rapidly modernising, healthcare system. Here, the "Founder Banker" often takes the form of a "Physician-Executive" or a "Hybrid Investor-Advisor," reflecting the region's emphasis on technical precision and clinical validity. ConAlliance: The Specialist Heavyweight ConAlliance dominates the M&A landscape for healthcare in the DACH region. While the firm operates as a traditional M&A boutique, its "founder" DNA is embedded in its sector exclusivity and the composition of its team, which includes physicians and engineers alongside bankers. Sector Depth: ConAlliance is strictly a healthcare advisor. They do not dilute their focus with other sectors. This allows them to maintain deep networks with family offices and specialised private equity firms that drive the German mid-market. The Model: Their approach is "relationship-driven" rather than purely transactional. In the DACH region, where businesses are often family-owned or founder-led for generations, the trust factor is paramount. ConAlliance's ability to speak the technical language of medical devices, specifically regarding the European Medical Device Regulation (MDR) compliance, is a key differentiator. The firm leverages partners like Prof. Dr. Dr. Ulrich Hemel and Prof. Christian Langbein, integrating academic and clinical prestige into their advisory offering, which is a highly valued currency in the German market. HGM Advisory: The Decentralised Expert Network HGM Advisory operates as a "decentralised network" of experts rather than a traditional bank, reflecting the "gig economy" evolution of high-level advisory. This model allows them to assemble "SWAT teams" for specific deals. The "Founder" Element: The network includes Dr. Andreas Schmidt, a biotech entrepreneur who founded and served as CEO of Proteona (single-cell sequencing), which was acquired by Singleron Biotechnologies. His presence brings recent, high-stakes transactional experience to the advisory table. Other members include Joscha, co-founder of Hacking Health Berlin, and Thomas Hagemeijer, a consultant with deep ties to the Springboard Health Angels. This structure allows HGM to offer highly specialised advice, deploying a regulatory expert for one deal and a biotech founder for another—without the overhead of a large bank. The French Ecosystem – Tech-Centricity and Research-Led Advisory France has established itself as a powerhouse for SaaS and AI, and its advisory landscape reflects this focus. The "Founder Bankers" here are often tech specialists who have deeply integrated into the startup ecosystem, treating HealthTech as a sophisticated vertical of the broader Digital Economy. Clipperton: The Research-Led Specialists Clipperton is the premier example of a tech-specialist bank that has successfully pivoted into HealthTech by treating it as a vertical of the "Digital Economy." The firm's approach is highly analytical, leveraging proprietary data to drive valuations. Antoine Ganancia (Managing Partner): Ganancia leads the HealthTech practice. While his background is in strategy consulting (Mars & Co) and Apple, his tenure at Clipperton (since 2010) has seen him orchestrate over 80 transactions. He operates with the mindset of a tech operator, applying rigorous SaaS metrics to healthcare businesses. His leadership has been pivotal in landmark deals such as the sale of Inova Software to Carlyle and the investment in DentalMonitoring by Merieux Equity. The Research Engine: Clipperton differentiates itself through proprietary research, such as the "European Health Tech Monitor." This thought leadership positions them as intellectual partners to founders, helping to frame the narrative around "Digital Sovereignty" and AI integration, key themes in French and European industrial policy. This research capability allows them to construct arguments for valuation premiums based on macro trends rather than just financial performance. The VC-to-PE Bridge : Clipperton excels in guiding companies from Venture Capital backing to Private Equity buyouts. This transition requires a specific skill set: translating the "growth story" of a VC asset into the "cash flow story" required by PE. Ganancia's team successfully executed this for Braincube (sale to Scottish Equity Partners) and Rydoo (sale to Eurazeo), demonstrating their ability to manage the complex stakeholder dynamics of a VC exit. Chausson Finance: The Pioneer of Fundraising Advisory Chausson Finance occupies a legendary spot in the French ecosystem. Founded by Christophe Chausson, a former VC, the firm invented the model of "fundraising advisory" for startups in France. The "Founder" Angle: Christophe Chausson is a serial entrepreneur in the financial services space. His team, including Laurence Hémery (who created a B2C travel app), embodies the "entrepreneurial" spirit. They focus almost exclusively on the "Equity Story", helping founders craft the narrative for VCs. This is upstream of M&A but critical in the lifecycle of a HealthTech company. Their "operator-first" style fosters strong partnerships with portfolio companies, ensuring sustainable growth and value creation long before an exit is considered. The Medical-Financial Convergence – MDs in Banking A parallel and equally significant trend to the "Founder Banker" is the recruitment of medical doctors (MDs) into senior investment banking and fund management roles. While these individuals may not be "founders" of startups in the traditional sense, they are "founders" of a new type of banking practice, one grounded in clinical science. The Rise of the Physician Banker at the Bulge Bracket The complexity of modern "TechBio" assets, where value is derived from biological mechanisms and AI algorithms, has rendered traditional financial due diligence insufficient. A spreadsheet cannot evaluate the efficacy of a cancer-detecting algorithm or the validity of a novel biomarker. Philippe Gallone (Goldman Sachs): Gallone is the archetype of this trend. A trained medical doctor from the University of Lausanne, he transitioned into banking and recently moved from Moelis & Company to become a Partner and Head of Healthcare Investment Banking in EMEA for Goldman Sachs. His appointment signals a strategic shift at Goldman. For "Mega Deals" involving Big Pharma and AI, the advisor must be able to debate clinical data on par with the Chief Scientific Officers of the acquiring companies. Gallone's medical background provides an "informational bridge" that reduces risk for the buyer and justifies premium valuations for the seller. He represents the "modern healthcare banker" who combines the scale of a global bank with the scientific literacy of a clinician. Dr. Moneer (BNP Paribas) : A senior healthcare banker with a PhD in Pharmacology from Cambridge. His career path emphasises the industry's demand for "Scientist-Dealmakers" who can shed light on business from a scientific perspective. Hedge Funds and the Search for "Edge" This trend extends beyond investment banking into the buy-side. Major multi-strategy hedge funds (Balyasny, Point72, Millennium) are aggressively hiring doctors and scientists in Europe. This "arms race" for medical talent is driven by the need for an "informational edge" in a volatile market. The logic is that an ex-doctor can better predict FDA approvals or clinical trial outcomes than a financial analyst. Founder-bankers and MD-bankers on the sell-side are the necessary response to this increasingly sophisticated buy-side audience; to sell to a fund managed by doctors, you need an advisor who can speak their language. Valuation Paradigms in a Founder-Led Era The entry of founder-bankers has fundamentally altered how HealthTech companies are valued. They have moved the conversation away from generic EBITDA multiples toward nuance-rich, sector-specific frameworks that account for the unique technological and regulatory characteristics of the sector. Deep Dive – Comparative Analysis of Advisory Models To assist founders and investors in navigating this landscape, we present a comparative analysis of the leading firms based on their "Founder DNA" and strategic focus. The Advisory Spectrum: A Matrix of Expertise Firm Operational Model Primary Persona "Founder" Credibility Source Deal Size Sweet Spot Key Differentiator Nelson Advisors "Founders for Founders" The Entrepreneurial Architect Lloyd Price / Paul Hemings: Direct founding & exit experience (Zesty, Neutrally). $25M - $250M Deep operational empathy; "Build/Buy/Partner/Sell" long-term strategy; focuses on Founder-led exits. Clipperton Research-Led Tech Specialist The Tech Translator Antoine Ganancia:Tech-centric career, massive deal volume, deep SaaS research. Mid-Market ($50M - $500M) "Dual Advisory" (Tech + Health); bridging the VC-to-PE gap; proprietary "Health Tech Monitor" data. Think.Health Investor-Advisor Hybrid The Hospital Insider Dr. Florian Kainzinger:Ex-CEO of Labor Berlin; manages active venture portfolio. Early to Mid-Market Unmatched access to German hospital infrastructure; implementation feasibility checks. ConAlliance Pure-Play Healthcare Boutique The Industry Veteran Team Composition:Includes physicians & engineers; exclusively healthcare. Mid-Market (DACH focus) Deep ties to DACH manufacturing/family offices; MDR/Regulatory expertise. Goldman Sachs Global Full-Service The Scientific Powerhouse Philippe Gallone (MD):Medical Doctor leading the practice. Large Cap ($1B+) Ability to speak "Science" at a mega-deal scale; global capital markets access; massive balance sheet. Future Outlook and Strategic Implications The "Distressed M&A" Wave and Consolidation As the market adjusts to the end of cheap capital, Europe is seeing a wave of consolidation. "Point solution fatigue" is driving hospital buyers to demand integrated platforms. The Founder-Banker Role: In distressed scenarios, the emotional intelligence of a founder-banker is critical. They can guide a failing founder through a "soft landing" or an "acqui-hire" with dignity, often leveraging their personal networks to find a home for the technology and team. This is a service that large banks, focused on fees, rarely provide effectively. Nelson Advisors, for instance, has actively guided buy-side clients on "roll-up" strategies to consolidate fragmented markets, creating value where generalists see only distress. The Rise of Secondary Markets With IPO windows remaining tight, "Continuation Vehicles" and secondary sales are becoming a primary exit route for VCs. Specialist Requirement: Valuing a secondary stake in a private HealthTech company requires deep insider knowledge of the asset's clinical progress. Founder bankers, who often sit on boards or maintain close ties with management, are better positioned to facilitate these opaque transactions than secondary market generalists. They can provide the "informational bridge" required to get a secondary buyer comfortable with the asset's long-term potential. Conclusion: A Permanent Shift The emergence of the founder banker is not a temporary phenomenon. It is a structural response to the increasing complexity of the HealthTech sector. As healthcare becomes more digital and biology becomes more engineering-driven, the barrier to entry for generalist advisors will continue to rise. For European founders, the choice of advisor is no longer just about "who can get the highest price." It is about "who understands my code, my clinical data and my journey." The firms profiled in this report, Nelson Advisors, Clipperton, Think.Health and their peers, represent the future of this symbiotic relationship between finance and innovation. They have successfully professionalised the role of the "Operator Advisor," ensuring that the next generation of European health champions has the guidance necessary to navigate an increasingly complex global market. Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk   Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @   https://www.healthcare.digital     We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb     Founders for Founders >  We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk   #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #BuySide   #SellSide #Divestitures   #Corporate   #Portfolio   #Optimisation   #SeriesA   #SeriesB   #Founders   #SellSide   #TechAssets   #Fundraising #BuildBuyPartner   #GoToMarket   #PharmaTech   #BioTech   #Genomics   #MedTech   Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk   Meet Us @ HealthTech events   October 2025 Healthcare Summit 2025, London, UK – Chairing the HealthTech M&A Panel Healthcare Summit 2025, London, UK – Chairing the HealthTech Deal Structuring Panel NHS Clinical Entrepreneur Conference, Belfast, Northern Ireland Global Health Exhibition 2025, Riyadh, Saudi Arabia – Chairing the HealthTech M&A Panel November 2025 HealthTech X Summit, London, UK – Chairing the “HealthTech predictions for 2026” Panel MedTech Europe 2025, Valletta, Malta- Speaker on the "Startups, Corporates & Hospitals: How to Build Meaningful MedTech Partnerships" panel MedTech Europe 2025, Valletta, Malta- Judge for the MedTech StartUp Pitch Awards Leaders in Health Summit 2025 December 2025 HealthTech Forward 2025, Barcelona, Spain – Moderating the Health Data Under Attack” Panel Healthcare Club, IESE Business School, Barcelona, Spain HealthInvestor Power List Awards 2025, London, UK – Judging Panel Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk

This Week in European HealthTech and MedTech: 19th December 2025 The biggest European MedTech developments this week centre on the EU’s proposed overhaul of MDR/IVDR, a broader Commission health package to boost innovation and resilience, and continued capital formation for MedTech and digital health scale‑ups.  Together these moves signal a more innovation‑friendly regulatory path and fresh growth funding for European MedTech heading into 2026.​ MDR/IVDR targeted revision The European Commission has proposed a targeted simplification of the Medical Devices Regulation (MDR) and In Vitro Diagnostics Regulation (IVDR) to make rules easier, faster and more effective while maintaining high patient safety.​ MedTech Europe welcomed the proposal as a “long‑awaited and necessary step” to fix parts of the system that are not working for patients, innovators and providers, highlighting the need to reduce bureaucracy and restore Europe’s competitiveness in MedTech.​ Wider EU health package The MDR/IVDR revision forms part of a broader Commission package of new measures aimed at creating an innovative and resilient health sector that delivers better outcomes across the EU.​ This package sits alongside initiatives like the Digital Omnibus and other digitalisation efforts, signalling a coordinated push to streamline health regulations, support data‑driven technologies and modernise procedures for medical technologies.​ Digital and AI regulatory alignment The Digital Omnibus proposals seek to rationalise how AI Act obligations interact with MDR/IVDR, as well as streamline data protection, cybersecurity and reporting frameworks that directly affect MedTech companies.​ Legal and policy analyses point out that this combination of Digital Omnibus and MDR/IVDR revision is intended to reduce regulatory fragmentation and over‑regulation that have been criticised for slowing innovation in European MedTech.​ Capital formation and scale‑up funding A €150 million co‑investment agreement between the European Investment Bank and Angelini Ventures, with €75 million from each, has been confirmed to finance European startups in biotechnology, MedTech and digital health.​ The vehicle aims to support seven to ten innovative European companies at market‑launch stage, directly addressing the late‑stage “valley of death” for MedTech and digital health scale‑ups.​ Operational and implementation themes Ongoing work around EUDAMED and MDR/IVDR implementation, including stepwise activation of database modules and extended transition periods for legacy devices, continues to shape day‑to‑day compliance planning for manufacturers and hospitals.​ These implementation changes are designed to prevent supply disruption while collecting better data on device availability, which will inform further tweaks to the regulatory framework through 2025–2026 . >>>  European HealthTech this week is defined by the Commission’s new health package and EHDS rollout, ongoing EU‑level digital health strategy, and continued investor focus on AI‑driven platforms and infrastructure. These themes reinforce a policy and funding environment that is increasingly supportive of data‑intensive HealthTech business models across the continent.​ EU health package and digitalisation The European Commission has proposed new measures to create an innovative and resilient health sector that “delivers for patients”, with digitalisation and data use as central pillars.​This sits alongside broader EU digital health work, where priorities include secure cross‑border access to health data, shared data infrastructure for personalised medicine, and citizen empowerment with digital tools.​ European Health Data Space (EHDS) Regulation (EU) 2025/327 formally establishing the European Health Data Space is now in force, laying down obligations for primary and secondary use of electronic health data across public and private actors.​ EHDS is expected to be structurally disruptive for HealthTech, enabling new business models in data‑driven care, research and AI, supported by a central MyHealth@EU interoperability platform for cross‑border EHR and e‑prescription exchange.​ EU funding and grant environment The EU has earmarked significant funding for digital health through programmes such as EU4Health and Digital Europe, with a strong focus on AI, interoperability, cybersecurity and cross‑border digital infrastructure.​ Specialist round‑ups highlight EU grants in 2025 targeting AI in healthcare, mental health and pandemic preparedness, providing non‑dilutive capital that can be blended with VC rounds for HealthTech startups.​ Market and investment signals Analyses of the 2025 HealthTech investment landscape show Europe attracting multi‑billion euro funding with healthtech among the most funded sectors, helped by EHDS and supportive digital policies.​ Funding commentators emphasise that roughly the majority of recent digital health capital is flowing into AI‑driven ventures and infrastructure plays, with reimbursement frameworks like DiGA and similar schemes in France and the Nordics seen as critical for scale‑up.​ Ecosystem initiatives and calls EIT Health’s 2025 “Digital Transformation of Healthcare” flagship call is directing money toward patient‑centred digital health solutions and evidence generation for CE‑marked digital medical devices entering EU markets.​ EU‑backed projects such as DigitalHealthEurope and related initiatives continue to feed recommendations into EHDS implementation, standards and coordination, shaping the environment for HealthTech vendors selling into national systems.​   Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk   Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @   https://www.healthcare.digital     We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb     Founders for Founders >  We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk   #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #BuySide   #SellSide #Divestitures   #Corporate   #Portfolio   #Optimisation   #SeriesA   #SeriesB   #Founders   #SellSide   #TechAssets   #Fundraising #BuildBuyPartner   #GoToMarket   #PharmaTech   #BioTech   #Genomics   #MedTech   Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk   Meet Us @ HealthTech events   October 2025 Healthcare Summit 2025, London, UK – Chairing the HealthTech M&A Panel Healthcare Summit 2025, London, UK – Chairing the HealthTech Deal Structuring Panel NHS Clinical Entrepreneur Conference, Belfast, Northern Ireland Global Health Exhibition 2025, Riyadh, Saudi Arabia – Chairing the HealthTech M&A Panel November 2025 HealthTech X Summit, London, UK – Chairing the “HealthTech predictions for 2026” Panel MedTech Europe 2025, Valletta, Malta- Speaker on the "Startups, Corporates & Hospitals: How to Build Meaningful MedTech Partnerships" panel MedTech Europe 2025, Valletta, Malta- Judge for the MedTech StartUp Pitch Awards Leaders in Health Summit 2025 December 2025 HealthTech Forward 2025, Barcelona, Spain – Moderating the Health Data Under Attack” Panel Healthcare Club, IESE Business School, Barcelona, Spain HealthInvestor Power List Awards 2025, London, UK – Judging Panel Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk

Nelson Advisors interviewed by Mergermarket: European healthcare M&A comeback in 2025 lays foundations for robust year ahead European healthcare M&A comeback in 2025 lays foundations for robust year ahead Europe’s healthcare M&A is poised to maintain strong momentum in 2026 following this year’s rebound in deal activity and renewed market confidence. “The sector is in a flywheel of productivity with drivers including ageing populations, workforce shortages, and technology adoption,” said Lloyd Price, Partner at Nelson Advisors. Following the turbulent tariff and regulatory environment at the start of 2025, the market is entering a period of relative confidence, he added. >> Pharma searches for blockbusters Biopharma has undeniably been given a turbo-boost by a craze over GLP‑1 agonists for their weight-loss effects as well as downstream protection from cardiovascular disease and diabetes, Price said. Patent cliffs in big pharma pipelines are driving acquisitions of potential new blockbusters, he added. Medical devices and equipment suppliers were an important driver of dealmaking this year as healthcare systems seek to cut labour costs and reduce massive elective care backlogs after the COVID-19 pandemic, Price said. The public healthcare backlog is leading to growth in private healthcare clinics, which then need their own consumables, Price said. Digital health is expected to see strong growth, with “blockbuster” digital health IPOs from US- based Hinge Health and Omada Health holding their prices. This rebuilds confidence in unit economics and profitability in public markets, Price said. >> Cross-border attractions A weaker pound and euro make European companies effectively cheaper for US buyers than domestic assets, Price said. Combined with improving financial performance, that’s a major draw right now, he added. Indeed, 2025 has seen an increase in inbound M&A, with volumes YTD up by a factor of 2.5 YOY from EUR 7.4bn in 2024 to EUR 18.1bn. AI impact on CROs, CDMOs double-edged sword "People want to catch up with the AI trend. Boards and CEOs are looking to buy a lot of tech and teams, ” Price said, citing ambient voice technology as an example. All in all, with clear fundamentals for dealmaking in place, supported by major demographic and sector digitalisation trends, the European healthcare market can look forward to a solid 2026. "We've had 18 months of surprises, so everyone's careful about making the wrong decision. But now the waters are calmer. What are we waiting for?" Price said. Source: https://mergermarket.ionanalytics.com/content/1004413200?source=news 'European healthcare M&A comeback in 2025 lays foundations for robust year ahead' by Jonathan Smith and Anahita Sawhney. Nelson Advisors interviewed by Mergermarket: European healthcare M&A comeback in 2025 lays foundations for robust year ahead

Why do founders and investors fear an AI bubble could burst in healthcare in 2026? Executive Summary: The Anatomy of a Market Reset The healthcare technology sector stands at a precipice. Following a period of unprecedented capital injection and exuberant valuation growth during 2024 and 2025, the market is careening toward a structural correction in 2026. This report argues that the feared "burst" of the healthcare AI bubble is not merely a cyclical downturn in venture sentiment but the mathematical inevitability of three converging forces: a regulatory cliff that imposes hardware-grade compliance costs on software startups, a maturation of financial obligations incurred during the peak of the hype cycle, and an operational "reality check" within health systems that is rapidly closing the window on the pilot-driven sales model. Founders and investors are right to fear 2026. The data indicates that while the top decile of "AI aristocrats", companies like Abridge, Xaira and Strive Health, have secured war chests sufficient to weather a downturn, the vast majority of the ecosystem is surviving on "unlabelled" bridge financing and unverified clinical promises. As we approach 2026, the transition from "promise" to "proof" will expose the fragile unit economics of AI-enabled services, which have been priced as high-margin SaaS platforms despite requiring significant human-in-the-loop intervention and facing elongated sales cycles. This report provides a comprehensive examination of the systemic risks coalescing in 2026. We analyse the "Four Os" of the bubble (Overinvestment, Overvaluation, Overownership, and Overleverage), detail the existential threat posed by the EU AI Act and FDA’s Quality Management System Regulation (QMSR) and dissect the "death by pilot" phenomenon that is starving early-stage ventures of revenue. Furthermore, we explore the aggressive entry of incumbents like Epic Systems into the AI space, a strategic shift that threatens to obliterate the market for point solutions. The conclusion is stark: 2026 will likely witness a mass extinction event for non-compliant, clinically unverified AI startups, clearing the field for a new era of industrial-grade, consolidated digital health infrastructure. Part I: The Macro Financial Distortions (2024-2025) To understand the severity of the looming 2026 correction, one must first dissect the financial anomalies of the preceding years. The investment landscape of 2024 and 2025 was characterised by a decoupling of capital deployment from fundamental market health, creating a "top-heavy" ecosystem vulnerable to collapse. The Bifurcation of Capital: Aristocrats vs. Zombies The headline numbers for digital health funding in 2025 paint a picture of robust health. By the third quarter of 2025, the sector had raised $9.9 Billion, surpassing the previous year's pace. However, a granular analysis reveals a dangerous concentration of this capital. Nearly 40% of the total funding volume was driven by just 19 "mega-deals" (investments exceeding $100 Million). Companies such as Strive Health ($550M), Judi Health ($400M), and Ambience Healthcare ($243M) absorbed the vast majority of available liquidity. This concentration suggests a "flight to safety" by limited partners (LPs) and venture capitalists (VCs). Rather than funding a broad base of innovation, capital has retreated into a narrow cohort of perceived winners. This leaves the "middle class" of startups, those needing $20-$50 Million Series B rounds to scale, starved for resources. In Q3 2025, Series B deal flow thinned dramatically, with only 30 raises recorded compared to an average of 63 in prior years. This "Series B Crunch" creates a demographic gap in the market; there are fewer companies graduating to maturity, while the early-stage pipeline remains bloated with seed-stage bets that have yet to face the scrutiny of growth equity investors. The "Unlabelled" Round Phenomenon: A Ticking Time Bomb Perhaps the most alarming indicator of hidden distress is the prevalence of "unlabelled" funding rounds. In 2025, approximately 35% of all digital health financings were unlabelled, meaning startups raised capital without assigning a specific series letter (eg. Series A, Series B) or disclosing valuation changes. Historically, unlabeled rounds are a symptom of a market in denial. Founders use them to extend runway without triggering the negative optical and anti-dilution consequences of a "down round." By avoiding a priced round, companies delay the mark-to-market realization of their true value. This creates a "noisy pipeline" where zombie companies (insolvent but funded) are indistinguishable from healthy ones. By 2026, the maturity on these bridge notes and unlabeled extensions will arrive. Investors who bridged companies in 2024 with the expectation of a 2026 recovery will face a binary choice: convert at a punitive discount or write off the asset. The sheer volume of these "kicked cans" suggests that 2026 will see a wave of forced liquidations and recapitalizations as the "extend and pretend" era ends. Macroeconomic Headwinds: The Maturity Wall Beyond the specific dynamics of venture capital, the broader macroeconomic environment poses a threat to the healthcare AI sector. The corporate debt market faces a "maturity wall" in 2026, where a significant volume of high-yield bonds and leveraged loans must be refinanced. Startups that utilised venture debt to avoid equity dilution during the ZIRP era will face a shock. If interest rates remain elevated, as forecasted by Vanguard, which projects a neutral rate of ~3.5% through 2026, the cost of refinancing this debt will be prohibitive. Venture debt lenders, facing their own liquidity constraints, will be less lenient with covenant breaches. This creates a scenario where startups with viable products but high burn rates are forced into bankruptcy by creditors, even if their equity investors are willing to continue support. The 2025 Capital Concentration Paradox Metric 2024 Status 2025 Status Implication for 2026 Total Funding (YTD Q3) $8.4 Billion $9.9 Billion superficially strong, but top-heavy. Mega-Deals ($100M+) <15 19 (39% of total $) Capital is hoarding in "safe" assets. Series B Deal Count ~63 (avg) 30 The "graduation" pipeline is broken. Unlabeled Rounds 37% 35% 1/3 of the market is hiding valuation reality. Average Deal Size $20.4M $28.1M Inflation of round size for the "winners." Sources: Rock Health, Galen Growth and PitchBook Data Part II: The Operational Crisis — "Death by Pilot" While financial engineering can sustain a company for quarters, operational reality ultimately dictates survival. For healthcare AI startups, 2026 represents the end of the "pilot era" and the onset of a brutal consolidation phase within health systems. Pilot Fatigue and the Failure to Convert For the past three years, health systems have been inundated with AI solutions. Hospital CIOs report managing dozens of simultaneous pilot programs, ranging from ambient scribes to predictive analytics for sepsis. While these pilots generate initial excitement (and press releases), conversion to enterprise-wide commercial contracts has been abysmal. The friction lies in the transition from "Proof of Concept" (POC) to production. A pilot in one department is relatively easy to approve; deploying a tool across a 20-hospital system requires deep EHR integration, rigorous cybersecurity reviews and demonstrable ROI that withstands CFO scrutiny. In 2025, health system executives explicitly signalled that "pilot fatigue is a real thing" and that they are aggressively cutting vendors that cannot scale. By 2026, the market expects a "collapse of point solutions". Hospitals are moving to rationalise their tech stacks, preferring to buy from platforms that offer multiple capabilities (e.g., Epic, Oracle, or broad platforms like Commure) rather than managing hundreds of disparate AI vendors. This shift is devastating for the "AI for X" startups (e.g., AI for scheduling, AI for coding), whose total addressable market (TAM) within a hospital is too small to justify the integration overhead. The "Integration Tax" and Incumbent Dominance The single biggest barrier to scaling healthcare AI is integration with the Electronic Health Record (EHR). Startups often underestimate the "integration tax", the time and capital required to build and maintain robust connections with Epic, Oracle (Cerner) and Meditech. In 2026, this dynamic shifts from a barrier to an existential threat as incumbents move to "eat" the market. Epic Systems, holding the records for a vast majority of US patients, has launched its own native ambient AI tools and integrated generative capabilities directly into the clinical workflow. If a health system can access an AI scribe within Epic for a marginal cost or as part of an existing license, the value proposition of a standalone competitor like Abridge or Nabla, charging premium SaaS fees, is severely eroded. History in healthcare IT (eg. the PACS market, the telehealth market) shows that "good enough" integrated solutions often kill superior point solutions. The "Platformisation" of AI in 2026 will force startups to either merge to gain scale or exit the market. The ROI Disconnect: Efficiency vs. Economics A critical driver of the 2026 burst is the realisation that "efficiency" does not always equal "savings." Many AI startups pitch "time saved" as their primary ROI metric (eg. "we save doctors 2 hours a day"). However, for a hospital CFO, time saved is only valuable if it translates to: Headcount reduction (which is rare due to unions and shortages), or Increased patient volume (which requires filling that saved time with billable visits). If an AI tool saves a doctor time, but that doctor simply goes home earlier (reducing burnout, but not increasing revenue), the hospital sees no hard financial return to pay for the software. As operating margins for hospitals remain razor-thin (hovering around 2.3% in late 2025), the 2026 budget cycle will see a ruthless culling of tools that offer "soft ROI" (burnout reduction) without "hard ROI" (cash flow). Why do founders and investors fear an AI bubble could burst in healthcare in 2026? Part III: The Regulatory Guillotine (2026 Deadlines) Unlike market sentiment, which is fluid, regulatory deadlines are fixed cliffs that carry civil and criminal penalties. The convergence of major US and EU regulations in 2026 creates a compliance burden that many early-stage AI companies are financially and operationally ill-equipped to handle. The European Union AI Act: The High-Risk Hammer On August 2, 2026, the full obligations of the EU AI Act for "High-Risk AI Systems" become enforceable.Virtually all clinical AI (medical devices, triage tools, patient monitoring) falls under this high-risk classification. The requirements are not trivial. They mandate: Conformity Assessments: Third-party audits by "Notified Bodies." Currently, there is a severe shortage of auditors qualified to assess complex generative AI models, guaranteeing a bottleneck that could freeze product launches for 12-18 months. Data Governance (Article 10): Providers must prove their training data is representative and free of bias. For startups that scraped US data to build models, proving relevance to EU demographics is a massive hurdle that may require retraining models from scratch. Transparency and Human Oversight: The "black box" nature of deep learning is legally challenged. Systems must be explainable to users, a technical challenge that remains unsolved for many LLMs. For a Series A startup, the cost of building this compliance infrastructure can exceed $1-2 Million annually. Companies that ignored this in 2024 to focus on growth will hit a "market blackout" in 2026, unable to operate in the EU and facing fines up to 7% of global turnover. FDA’s Quality Management System Regulation (QMSR) In the United States, the FDA is harmonising its requirements with international standards via the Quality Management System Regulation (QMSR), effective February 2, 2026. This rule aligns FDA 21 CFR Part 820 with ISO 13485:2016. This transition forces "Software as a Medical Device" (SaMD) companies to adopt hardware-grade quality systems. Design Controls: Every iteration of an algorithm must be documented, validated, and verified. The agile methodology ("move fast and fix it later") is fundamentally incompatible with QMSR. Supplier Controls: Startups relying on third-party APIs (like OpenAI's GPT-4) must treat these as "suppliers" and verify their quality. This creates a "dependency risk": if OpenAI changes its model weights, the medical device effectively changes, triggering a need for re-validation. The FDA is also finalising guidance on Predetermined Change Control Plans (PCCP) for AI/ML. While this allows for some iterative updates, it requires rigorous pre-market planning and post-market monitoring for "data drift" (performance degradation over time). Startups that deployed "static" models without continuous monitoring infrastructure will face enforcement actions, warning letters, and potential recalls in 2026. The Prior Authorisation Crackdown (CMS-0057-F) Effective January 1, 2026, the CMS Interoperability and Prior Authorisation Final Rule (CMS-0057-F) mandates that payers implement FHIR-based APIs to streamline decision-making. While ostensibly a modernisation effort, this rule threatens the business models of "middleman" startups that built businesses around manual prior authorisation workarounds (e.g., fax automation, screen scraping). The rule forces a shift to standardised APIs, favouring players with deep interoperability expertise. Furthermore, CMS is launching the WISeR pilot in 2026 to police the use of AI in denials, increasing scrutiny on payers and the vendors they use. AI startups that sold "denial optimisation" tools to insurers may find their algorithms illegal or heavily restricted under these new transparency mandates. The Regulatory Convergence of 2026 Regulation Effective Date Core Requirement Impact on Startups CMS Prior Auth Rule (0057-F) Jan 1, 2026 Mandatory FHIR APIs for payers; 72-hour turnaround. Obsoletes legacy "screen scraping" automation models. FDA QMSR (ISO 13485) Feb 2, 2026 Alignment of Quality Systems with global standards. Increases overhead; "agile" dev teams must adopt rigorous controls. EU AI Act (High-Risk) Aug 2, 2026 Full compliance with risk, data, and oversight rules. "Market blackout" for non-compliant firms; heavy fines. PCCP Guidance Ongoing 2026 Continuous monitoring for algorithmic drift. Requires perpetual "re-validation" of models in the wild. Part IV: The Reimbursement Mirage & Policy Headwinds A central pillar of the "AI Bull Case" has been the expectation of widespread reimbursement. Investors have poured capital into startups on the premise that "CPT codes are coming." However, an analysis of the 2026 regulatory landscape reveals that reimbursement is a mirage for most. The Trap of Category III Codes The American Medical Association (AMA) has indeed released new CPT codes for 2026 covering AI-augmented services (eg. ECG analysis, remote monitoring). However, the vast majority of these are Category III codes. Category III codes are temporary tracking codes used to collect data on emerging technologies. Critically, they rarely carry a guaranteed payment value. CMS and private payers often consider them "experimental" and deny coverage. Startups that built revenue models assuming they could bill for these codes are discovering that they are essentially "data donors" to the system, performing services for free to prove value to CMS years down the line. The 2026 Physician Fee Schedule: Paying Doctors, Not Algorithms The CY 2026 Medicare Physician Fee Schedule (PFS) introduces new codes for "Advanced Primary Care Management" (APCM) and creates separate conversion factors for APM participants. While this supports the practice of advanced care, the revenue flows to the provider, not the technology vendor. This distinction is vital. In a value-based care environment, providers are incentivised to reduce costs. They will only pay for AI tools that are cheaper than the labor they replace. They will not pass through a "technology fee" to the vendor unless the ROI is indisputable. This squeezes the pricing power of AI startups, forcing them to compete on price rather than value, further compressing margins that were already overstated in 2024 valuations. The "AI as a Service" Reimbursement Void There remains no dedicated "AI CPT code" that pays a vendor directly for running an algorithm. The 2026 updates modernise coding for procedures involving AI (like image guidance), but they do not create a SaaS-like revenue stream. The "software as a service" business model in healthcare is colliding with a "fee for service" reimbursement system that refuses to pay for software separately from the medical act. This misalignment is a primary driver of the revenue shortfalls expected to trigger the 2026 bubble burst. Part V: Clinical Reality & The Trust Deficit The financial and regulatory pressures of 2026 are compounded by a growing crisis of confidence in the clinical validity of AI tools. The Recall Crisis: "People Become the Test" Recent studies analysing FDA-authorised AI devices have revealed alarming safety gaps. A study from Johns Hopkins found that 43% of AI medical device recalls occurred within the first year of authorisation. More damningly, nearly all recalled devices from small, private companies lacked robust clinical validation data (published trials) prior to market entry. This "ship first, validate later" culture, often imported from the tech world is backfiring. Health systems are realising that they have become the de facto testing grounds for unproven algorithms. In 2026, hospital procurement committees are instituting "Impact Cards" and demanding peer-reviewed evidence before signing contracts. This raises the barrier to entry significantly; a startup can no longer sell on a demo; it needs a clinical trial, which costs millions and takes years. The "Human-in-the-Loop" Economic Drag To mitigate the risks of hallucinations and algorithmic bias, health systems are demanding "Hybrid Intelligence" models, where humans validate every AI output. While clinically safer, this destroys the economic thesis of many AI startups. If an AI scribe requires a human reviewer to check the note for accuracy (as is the case with many "AI-enabled" services), the gross margins of the business look like a services firm (30-40%) rather than a software firm (80%+). Yet, these companies raised capital at software multiples (20x-50x revenue). In 2026, as these low margins become undeniable in financial reports, valuations will undergo a violent correction to match the "tech-enabled services" reality. Algorithmic Drift and Maintenance Costs AI models are not static; they degrade as patient populations and clinical practices change (a phenomenon known as "data drift"). The FDA's new focus on this via the PCCP guidance means that companies must continuously invest in re-training and monitoring their models. This introduces a "maintenance capex" that traditional software does not have. The cost of goods sold (COGS) for an AI product is structurally higher than SaaS, further compressing the margins that investors are banking on. Part VI: Competitive Dynamics — Incumbents vs. Insurgents The final catalyst for the 2026 burst is competitive. The incumbents have woken up. Epic's "Watershed Moment" Epic Systems' launch of native ambient AI capabilities is described as a "watershed moment" for the industry.Epic's integration advantage is insurmountable for most startups. They control the interface, the data flow and the security perimeter. For a hospital, turning on an Epic feature is a "one-click" operational decision. Bringing in a third-party vendor like Abridge or Suki involves legal review, security audits, business associate agreements (BAAs), and interface costs. Unless the startup's performance is orders of magnitude better than the incumbent, the path of least resistance wins. We expect 2026 to be the year where "good enough" incumbent AI wipes out "best of breed" point solutions. The "Wrapper" Extinction A significant portion of the 2024 funding wave went to "wrapper" startups, companies that built thin user interfaces on top of foundational models like GPT-4 or Claude. These companies have no proprietary data moat. As foundational models improve and become cheaper, or as hospitals build their own internal interfaces using Azure/OpenAI instances, the value of these wrappers falls to zero. 2026 will see the commoditisation of "generic" healthcare AI, leaving only those with deep, proprietary, vertical-specific datasets standing. Part VII: Case Studies in Failure — The Ghosts of Future Past To predict the trajectory of 2026, one need only look at the high-profile failures that have already occurred. These serve as leading indicators of the systemic weaknesses in the market. Olive AI: The $4 Billion Cautionary Tale Olive AI liquidated in late 2023 after raising over $850 million and reaching a $4 billion valuation. Its failure was driven by: Overpromising: Selling "AI" that was often brittle robotic process automation (RPA). Lack of Focus: Expanding into prior auth, claims, and population health simultaneously. Unit Economics: The cost of maintaining the bots exceeded the revenue they generated. Olive is the archetype for the current generative AI boom. Many current darlings are replicating Olive's mistake of selling a vision of "total automation" that their technology cannot reliably deliver, leading to churn and eventual insolvency. Babylon Health: The "AI Doctor" Fallacy Babylon Health's bankruptcy in 2023 exposed the dangers of taking on financial risk based on unproven AI. Babylon claimed its AI could triage patients better than doctors, but when it signed value-based care contracts, the AI failed to control costs. The lesson for 2026 is that valuation does not equal durability. If the technology cannot fundamentally bend the cost curve in a way that shows up on a P&L statement, the business model is a house of cards. The "Zombie" Apocalypse Data from 2025 shows a sharp rise in "zombie" startups, companies that are technically active but have stagnant growth and no exit path. Shutdowns increased by over 25% in 2024/2025. These companies are currently hoarding talent and burning remaining cash, but the 2026 funding cliff will force them into liquidation. The ecosystem simply cannot support the number of distinct vendors currently funded; a culling is mathematically necessary. Part VIII: Conclusion & Strategic Outlook The fear of an AI bubble bursting in healthcare in 2026 is not paranoia; it is a rational response to the convergence of inflated expectations, regulatory hardening and financial gravity. The market is transitioning from a phase of Exploration (2023-2025) characterised by easy funding, pilot programs and hype, to a phase of Industrialisation (2026 onwards). In this new phase, the metrics for success shift from "number of pilots" to "audited ROI," from "algorithm accuracy" to "clinical validity," and from "growth at all costs" to "QMSR compliance." The 2026 "Burst" will manifest as: A Wave of Bankruptcies: Specifically among "wrapper" startups and point solutions that failed to integrate or prove clinical utility. Distressed M&A: Incumbents (Epic, Oracle, UnitedHealth) and "AI Aristocrats" (Abridge, etc.) will acquire failing startups for their talent and IP, often at pennies on the dollar. Valuation Resets: Down rounds will become the norm as investors re-price AI services companies with "tech-enabled services" multiples rather than SaaS multiples. For the survivors, those who invested early in compliance, clinical validation and deep integration, the post-bubble era offers immense opportunity. The demand for healthcare efficiency is real and urgent. But the supply of solutions must undergo a purification by fire. The bubble will burst, washing away the noise, leaving behind the bedrock of true clinical utility. Key Watchlist for 2026 The "Unlabelled" Ratio: If >30% of rounds remain unlabelled in late 2025, expect a violent correction. EU Notified Body Wait Times: Increasing delays signal a regulatory bottleneck that will kill cash-poor startups. Epic's AI Adoption Metrics: Rapid uptake of Epic's native tools is a leading indicator of point solution collapse. Hospital Operating Margins: If margins stay below 3%, IT budgets will contract, accelerating vendor consolidation. Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events October 2025 Healthcare Summit 2025, London, UK – Chairing the HealthTech M&A Panel Healthcare Summit 2025, London, UK – Chairing the HealthTech Deal Structuring Panel NHS Clinical Entrepreneur Conference, Belfast, Northern Ireland Global Health Exhibition 2025, Riyadh, Saudi Arabia – Chairing the HealthTech M&A Panel November 2025 HealthTech X Summit, London, UK – Chairing the “HealthTech predictions for 2026” Panel MedTech Europe 2025, Valletta, Malta- Speaker on the "Startups, Corporates & Hospitals: How to Build Meaningful MedTech Partnerships" panel MedTech Europe 2025, Valletta, Malta- Judge for the MedTech StartUp Pitch Awards Leaders in Health Summit 2025 December 2025 HealthTech Forward 2025, Barcelona, Spain – Moderating the Health Data Under Attack” Panel Healthcare Club, IESE Business School, Barcelona, Spain HealthInvestor Power List Awards 2025, London, UK – Judging Panel Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

Nelson Advisors: European HealthTech M&A Advisory – 2025 Year in Review Executive Summary: Central architect of the European HealthTech landscape for years to come The fiscal and calendar year of 2025 represented a definitive structural transformation for the European Healthcare Technology (HealthTech) and Medical Technology (MedTech) sectors. Following the volatile corrections of 2023 and the tentative stabilisation of 2024, the market in 2025 settled into a rigorous "flight to quality," characterised by a stark bifurcation in asset valuations and a profound shift in investor sentiment. In this complex, metric-driven environment, Nelson Advisors solidified its standing not merely as a transactional intermediary, but as a strategic architect for high-growth ventures and institutional investors alike. This report provides an analysis of Nelson Advisors' activity, market influence and strategic positioning throughout 2025. The analysis indicates that the firm’s proprietary "Founders for Founders" operational model was the decisive factor in its 2025 success. By leveraging the direct entrepreneurial pedigrees of partners Lloyd Price and Paul Hemings, Nelson Advisors successfully navigated a market where generalist advisory firms struggled to bridge the widening gap between technical complexity and commercial viability. The firm effectively capitalised on the "AI Premium," guiding clients through the intricacies of the EU AI Act and the nascent "Ambient Voice Technology" landscape, while simultaneously managing the grim realities of the distressed M&A wave that comprised nearly a third of all deal flow. As the sector transitioned from "growth-at-all-costs" to "path-to-profitability," Nelson Advisors emerged as a primary source of truth for valuation metrics and strategic foresight. This report dissects the firm's multifaceted performance, exploring its deal log, its thought leadership on deal failures and its predictions for the "Mega Deals" of 2026, offering a granular view of an advisor operating at the bleeding edge of the European health economy. Operational DNA: The Practitioner-Led Differentiator In an investment banking landscape often dominated by career financiers and generalist institutions, Nelson Advisors has cultivated a distinct identity rooted in the operational experience of its leadership. The firm’s "Founders for Founders" philosophy is not merely a marketing tagline but a fundamental operational differentiator that dictates its approach to client selection, deal structuring and negotiation strategy. The firm is led by two partners whose backgrounds span the full spectrum of the HealthTech lifecycle, from early-stage ideation to large-cap corporate finance. Lloyd Price (Partner & Co-Founder): Price brings a rare dual competency in consumer internet dynamics and clinical healthcare. His background includes foundational roles at consumer tech giants like Yahoo and Kelkoo, providing him with deep insight into user engagement metrics, a critical KPI for digital health platforms. However, his credibility in the HealthTech space is anchored by his entrepreneurial track record, specifically the founding and scaling of Zesty, a patient engagement platform. Price successfully exited Zesty in 2020 to Induction Healthcare Group PLC (FTSE: INHC), a transaction that provides him with direct "skin in the game" experience regarding the complexities of selling a venture-backed company to a publicly listed strategic acquirer. Furthermore, his role as a Health Executive in Residence at the UCL Global Business School for Health cements his influence within the academic and clinical innovation ecosystem, allowing the firm to bridge the gap between commercial imperatives and clinical validation. Paul Hemings (Partner & Co-Founder): Hemings complements Price’s operational agility with the structural rigor of a bulge-bracket investment banker. With over a decade of experience in global M&A and capital raising, Hemings has executed over $50 Billion in M&A and $40 billion in equity/financing transactions across the US, UK, Europe, and Asia. His tenure at Credit Suisse and Invesco equipped him with the technical sophistication required for complex cross-border deals. Crucially, Hemings also possesses entrepreneurial experience, having founded and exited two early-stage companies, including Neutrally, a metabolic HealthTech venture and Bird Restaurants. This unique blend allows him to apply institutional-grade financial engineering to the often chaotic reality of early-stage scaling, a capability that was particularly vital in 2025 as the market demanded more creative deal structures involving earn-outs and equity rolls. This "Founders for Founders" model allows Nelson Advisors to offer a level of "operational empathy" that pure-play financial advisors cannot replicate. In 2025, where deal friction was high due to valuation resets, the partners' ability to manage the psychological and emotional aspects of founder exits was as critical as their financial modelling. The "Build, Buy, Partner, Sell" Strategic Framework Throughout 2025, Nelson Advisors operated under a holistic consultative framework dubbed "Build, Buy, Partner, Sell." This approach challenges the traditional advisory model, which is typically biased toward pushing for an immediate transaction to secure success fees. Instead, the firm positions itself as a long term strategic partner, advising clients on the complete corporate lifecycle to maximize shareholder value. Build: The firm advises on organic growth strategies, helping companies determine if they have reached the necessary "Integrated HealthTech Fit" (Founder-Market, Product-Market, Regulatory-Market) to scale independently. In 2025, this often meant advising companies to delay exits until they could demonstrate a clear "Rule of 40" financial profile. Buy: With the fragmentation of the European HealthTech market, Nelson Advisors actively guided buy-side clients on "Roll-Up" strategies. The firm identified that hospital CIOs and payers were suffering from "point solution fatigue," driving a need for consolidated platforms. Partner: Recognising that M&A is not the only route to value, the firm structured strategic alliances and channel partnerships. This was particularly relevant for accessing new markets or validated clinical data without the capital intensity of an acquisition. Sell: When the timing was optimal, the firm managed the full exit process, from valuation and positioning to negotiation and closure. The firm’s "sell-side" advisory in 2025 was characterised by a focus on "defensible value," ensuring that clients could withstand the rigorous due diligence of the "flight to quality" era. Brand Clarity and Market Segmentation Nelson Advisors LLP is strictly a Healthcare Technology M&A advisory firm. It does not function as a law firm (distinguishing it from Nelson Mullins, which also has a robust M&A practice) or a generalist investment advisor. This singular dedication to HealthTech, covering Digital Health, Health IT, Consumer Health, Healthcare AI and Cybersecurity, contrasts sharply with generalist firms. This specialisation allows for a mastery of sector-specific regulations (such as the EU AI Act) and technological trends that generalists cannot replicate. The firm’s focused dedication forms the bedrock of its value proposition, enabling a nuanced understanding of technological advancements and market dynamics critical for successful transactions within this complex industry. The End of ZIRP and Valuation Bifurcation The overarching economic theme of 2025 was the definitive end of the "Growth at All Costs" era, which had been fuelled by the Zero Interest Rate Policy (ZIRP) of the previous decade. In its place, 2025 established a "Flight to Quality" environment where capital efficiency, unit economics, and proven clinical utility became the primary determinants of value. Nelson Advisors' research highlights a dramatic bifurcation in the market. Assets deemed "Premium", characterised by profitability, proprietary AI (as opposed to generic "wrappers"), and mission-critical infrastructure, commanded high multiples. Conversely, unprofitable pure-play companies or those with undifferentiated technology faced severe valuation compression, often trading at or below their invested capital. HealthTech Valuation Multiples (December 2025) Asset Class Valuation Metric Multiple Range Strategic Driver & Market Rationale Premium AI & Data EV / Revenue 6.0x – 8.0x+ Companies with proprietary algorithms (e.g., drug discovery, imaging AI) and clean, actionable datasets. Buyers pay a premium for "defensibility" and the ability to commoditize services. Value-Based Care (VBC) EV / Revenue 5.5x – 7.0x Platforms enabling risk-bearing models (e.g., population health, remote monitoring) that demonstrate hard ROI for payers and cost reduction. Hybrid Telehealth EV / Revenue 5.0x – 7.0x Mature platforms combining virtual care with in-person capabilities. Pure-play virtual care trades significantly lower due to commoditization. General HealthTech SaaS EV / Revenue 4.0x – 6.0x The "standard" range for growing digital health software with average retention and margins. Unprofitable / Early Stage EV / Revenue 3.0x – 4.0x Startups with high burn rates or unclear paths to profitability. These companies face significant compression and are often candidates for distressed M&A. Profitable HealthTech Software EV / EBITDA 10x – 14x Established software firms with >20% EBITDA margins and high stickiness (meeting the "Rule of 40"). Tech-Enabled Services EV / EBITDA 10x – 12x Service-heavy models (e.g., RCM, provider services) that scale slower than pure software but offer cash flow stability. Broader Healthcare Services EV / EBITDA ~12.8x Median across the wider healthcare sector, including hospitals and mature services. Source: Nelson Advisors Research, December 2025 This data illustrates that the spread between top-tier and median assets was wider in 2025 than in any previous year. The "AI Premium" was highly selective: buyers paid for technology that could effectively replace human labor in revenue cycle management or diagnostics, while discounting "wrapper" companies that merely placed a thin interface over generic Large Language Models (LLMs). Four Key "Levers" Driving Valuations Nelson Advisors identified four specific variables that determined where a company fell within the valuation ranges in 2025: The "AI Premium" (Real vs. Hype): Investors aggressively scrutinized the proprietary nature of AI. Validated, defensible algorithms commanded the highest premiums, while those reliant on third-party APIs were viewed as commodities. Profitability & Unit Economics: The primary metric shifted to capital efficiency. Companies with a clear "Rule of 40" score (Growth % + EBITDA % > 40) received competitive term sheets. Those burning cash without a sub-18-month path to breakeven faced down-rounds or distressed exits. Vendor Consolidation (The "Platform" Play): Hospital CIOs and payers expressed "point solution fatigue," desiring fewer vendors doing more. Single-point solutions (e.g., a niche diabetes app) traded at lower multiples unless acquired to be tucked into a larger platform. Comprehensive platforms (e.g., "MSK + Mental Health + Chronic Care") were valued higher. Regulatory & Antitrust Scrutiny: Increased scrutiny from the FTC, DOJ, and EU regulators regarding healthcare consolidation and data privacy (specifically the EU AI Act) created a "regulatory risk premium." Deals involving significant data aggregation or vertical integration took longer to close and often required complex earn-out structures to mitigate risk. The Distressed M&A Landscape and Deal Failure Analysis The Surge in Distressed Assets (20-30% of Market) A defining, albeit somber, characteristic of the 2025 landscape was the surge in distressed M&A. Nelson Advisors reported that by December 2025, distressed deals accounted for approximately 20-30% of total HealthTech M&A activity. This trend was driven by the "Series A Crunch." Many companies that had raised seed capital during the pandemic boom failed to meet the rigorous performance metrics required for Series A funding in the tighter 2025 capital environment. Nelson Advisors estimated that 25% to 35% of M&A deals in the UK involved companies selling for less than the total capital invested in them. This environment created a "buyer's market." Private Equity firms and strategic acquirers (including NHS-aligned players) utilized "Buy and Build" strategies to acquire innovative technology at bargain-basement valuations. For example, firms like Kester Capital capitalised on this by acquiring assets to consolidate fragmented spaces like pharma services. While painful for early-stage founders, Nelson Advisors viewed this as a necessary consolidation, moving technology from fragile startups into stronger hands capable of scaling it. Anatomy of Deal Failure: The "10 Reasons" Analysis In a widely cited piece of thought leadership, Nelson Advisors analysed the "anti-portfolio", deals that failed to close in 2025. This analysis provided a roadmap for founders to avoid pitfalls, identifying that failures were driven primarily by valuation gaps and due diligence deterioration rather than a lack of strategic appetite. The 10 Key Reasons for Deal Failure in 2025: Valuation Gaps & Reset of Multiples: Unbridgeable gaps between sellers anchoring to 2021 "peak" valuations and buyers pricing off conservative 2025 profitability metrics. Deterioration During Due Diligence: Deeper diligence revealing weak unit economics, aggressive revenue recognition, or unresolved quality system issues (CAPAs) in MedTech targets. Regulatory & Compliance Hurdles: Heightened scrutiny on data privacy (GDPR/HIPAA), AI governance, and cross-border data transfers making deals too risky. Macroeconomic & Financing Uncertainty: Volatile inflation and tariff risks keeping financing costs high, leading to tougher credit committees and tighter leverage tolerance. Misaligned Strategic Rationale: Vague "digital transformation" deals being abandoned in favor of bolt-ons that clearly filled portfolio gaps. Integration & Technology Platform Risk: The complexity and cost of migrating customers and clinical workflows proving higher than anticipated. AI, Data, and IP Uncertainty: Questions around ownership of training data and algorithm explainability leading acquirers to step back from AI-native targets. Reimbursement & Commercial Traction Risk: Fragile revenue forecasts due to slower-than-expected adoption of virtual care and reimbursement shifts. Governance, Founder, and Culture Clashes: Founders resisting governance changes or earn-out structures, leading to a breakdown in trust. Execution Fatigue & Process Design: Lengthy processes and internal pipeline crowding leading to deal fatigue and deprioritization of marginal opportunities. This analysis underscores the firm's role in managing expectations. By publicising these failure points, Nelson Advisors positions itself as a realist advisor that prepares clients for the "ugly" parts of a transaction, thereby increasing the probability of closing. Strategic Thought Leadership and Market Influence In 2025, Nelson Advisors leveraged its research capabilities as a primary business development tool, establishing itself as a "knowledge hub" for the industry. The firm's insights were cited by major consulting firms like Deloitte and intelligence services like Mergermarket. The "Integrated HealthTech Fit" Model Moving beyond the standard startup concept of "Product-Market Fit," Nelson Advisors introduced the "Integrated HealthTech Fit Model" in 2025. This framework argues that successful HealthTech ventures must achieve equilibrium across three pillars to be investable or acquirable Founder-Market Fit: Defined by obsession with the problem, personal history (often a family medical experience), and deep sector experience, not just a desire for "disruption." Product-Market Fit: Validated not just by users but by clinical utility and a multi-stakeholder value proposition that addresses the needs of patients, providers and payers. Regulatory-Market Fit: Integrating compliance as a core business strategy to build competitive moats. In 2025, a great app with no reimbursement pathway or regulatory clearance was structurally un-investable. Ambient Voice Technology and the NHS Specific attention was paid to "Ambient Voice Technology" (AVT) or AI Scribes. Nelson Advisors identified this as a critical enabler for the NHS 10-Year Plan published in July 2025. The firm argued that AVT's ability to alleviate administrative burden aligns perfectly with government mandates for productivity and the shift from analogue to digital care models. Consequently, the firm predicts significant M&A activity in this sub-sector as large Electronic Patient Record (EPR) providers look to acquire best-in-class independent AI scribe solutions to integrate into their stacks. Industry Presence: Events and Awards The firm's partners maintained a high-profile presence at major industry events, influencing the discourse around the future of HealthTech: IESE Business School (Barcelona, Dec 2025): Lloyd Price chaired the "Finance in Healthcare" panel, discussing investment strategies with peers from firms like Careventures and Google's Startup Growth Lab. This engagement places the firm at the center of the European academic and business conversation. HealthTechX 2025 (London, Nov 2025): Lloyd Price chaired the "HealthTech Predictions for 2026" panel. This session tackled critical questions regarding the EU AI Act's impact on deployment and the potential for consolidation by major hospital groups and Pharma. HealthInvestor Awards 2025: For the second consecutive year, Lloyd Price served as a judge for these prestigious awards. This role signifies peer recognition of expertise and provides the firm with deep visibility into the best-performing companies in the sector. Future Health Intelligence: The firm participated in webinars analyzing the key changes shaping 2025 and predicting trends for the 2026-27 NHS financial year, specifically regarding the £10 billion committed in the Spending Review. Competitive Landscape: The Boutique Advantage In the 2025 landscape, Nelson Advisors operated within a competitive ecosystem including specialised boutiques like Clipperton, Arma Partners, and Lincoln International, as well as global giants like Goldman Sachs. Comparative Analysis of European HealthTech Advisors Firm Primary Focus Competitive Differentiator 2025 Strategic Positioning Nelson Advisors HealthTech / MedTech "Founders for Founders" DNA Dominant in Founder-led exits and distressed M&A; Strong grasp of early-stage scaling dynamics and AI/TechBio nuance. Clipperton Tech & Digital Cross-border European reach Strong in broader digital sectors; often competes on larger SaaS mandates. Lincoln International Mid-Market Global Dual expertise (Services + IT) Excels where "Healthcare Services" and "IT" blur (e.g., dental groups with software); strong in PE-backed roll-ups. Goldman Sachs Large Cap / Global Balance Sheet & Scale Leads the largest transformative deals (Mega Deals); less focused on the granular mid-market founder exits. Arma Partners Digital Economy Deep Tech focus Strong track record in software and data infrastructure deals across the digital economy. Nelson Advisors differentiates itself through its "Dual Advisory Model" of scale versus specialization. While Goldman Sachs leads by value and strategic transformation, and Rothschild & Co leads by volume, Nelson Advisors (along with firms like Artis Partners) captures the market for specialised AI and DeepTech mandates. The firm’s "Founders for Founders" model allows it to win mandates from entrepreneurs who prioritise operational empathy and sector nuance over the sheer balance sheet capability of a bulge-bracket bank. Future Outlook: 2026 and Beyond Looking ahead to 2026, Nelson Advisors predicts a shift from the volume-driven, lower-value dealmaking of 2024-2025 to high-value, transformative transactions. The firm forecasts a substantial increase in Mega Deals ($5 Billion and above) as credit conditions improve and CEO confidence returns. This will be driven by a need to counter macroeconomic headwinds and shore up EBITDA margins through scale. Big Tech Market Entry & The "Digital Left Shift" The firm anticipates a resurgence of Big Tech (Amazon, Google, Apple) acquiring HealthTech companies specialised in interoperability and patient-facing apps. This is driven by the strategic imperative to secure real-time patient data and align with upcoming frameworks like the CMS FHIR API 2026 mandates. This trend aligns with the "Digital Left Shift," where care moves from hospitals to the home and community, powered by technology. Regulatory Catalysts: EU AI Act & EHDS The full implementation of the EU AI Act and the European Health Data Space (EHDS) in 2026 will serve as major catalysts. While initially creating friction, these frameworks will ultimately unlock the secondary use of health data for AI training at scale. Nelson Advisors predicts that companies who have navigated the "high-risk" classification of the AI Act will become prime acquisition targets for larger players seeking compliant, de-risked AI assets. Conclusion The year 2025 was a crucible for the European HealthTech sector. It separated the "hype" from the "happening," the "wrappers" from the "proprietary," and the "growth tourists" from the "industry natives." In this unforgiving environment, Nelson Advisors demonstrated that deep specialisation and operational experience are the ultimate competitive advantages. By adhering to its "Founders for Founders" ethos, the firm successfully guided clients through a treacherous valuation landscape, managing everything from the recapitalization of UK biotech to the intricacies of US-listed cross-border financings. As the market pivots toward the "Mega Deals" predicted for 2026, Nelson Advisors' entrenched position, strategic foresight and demonstrated ability to execute complex transactions suggest it will remain a central architect of the European HealthTech landscape for years to come. Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk   Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @   https://www.healthcare.digital     We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb     Founders for Founders >  We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk   #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #BuySide   #SellSide #Divestitures   #Corporate   #Portfolio   #Optimisation   #SeriesA   #SeriesB   #Founders   #SellSide   #TechAssets   #Fundraising #BuildBuyPartner   #GoToMarket   #PharmaTech   #BioTech   #Genomics   #MedTech   Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk   Meet Us @ HealthTech events   October 2025 Healthcare Summit 2025, London, UK – Chairing the HealthTech M&A Panel Healthcare Summit 2025, London, UK – Chairing the HealthTech Deal Structuring Panel NHS Clinical Entrepreneur Conference, Belfast, Northern Ireland Global Health Exhibition 2025, Riyadh, Saudi Arabia – Chairing the HealthTech M&A Panel November 2025 HealthTech X Summit, London, UK – Chairing the “HealthTech predictions for 2026” Panel MedTech Europe 2025, Valletta, Malta- Speaker on the "Startups, Corporates & Hospitals: How to Build Meaningful MedTech Partnerships" panel MedTech Europe 2025, Valletta, Malta- Judge for the MedTech StartUp Pitch Awards Leaders in Health Summit 2025 December 2025 HealthTech Forward 2025, Barcelona, Spain – Moderating the Health Data Under Attack” Panel Healthcare Club, IESE Business School, Barcelona, Spain HealthInvestor Power List Awards 2025, London, UK – Judging Panel Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk

The Digital Musculoskeletal (MSK) Market Transformation Forecast 2026–2035 Strategic Outlook: The Digital Musculoskeletal (MSK) Market Transformation (2026–2035) The global healthcare landscape is rapidly converging upon a singular, undeniable crisis point regarding musculoskeletal (MSK) health, creating a definitive "before and after" scenario centred around the year 2026. For decades, MSK disorders, encompassing conditions ranging from non-specific low back pain (LBP) to complex post-surgical rehabilitation, have served as the silent epidemic of the industrialized world. However, as we approach the latter half of the 2020s, the convergence of aging demographics, workforce health crises, and unsustainable surgical costs has transformed this clinical category into a primary driver of global healthcare innovation. The digital MSK market, once a niche segment of the broader telehealth revolution, is now forecasted to undergo massive, systemic growth, driven not merely by convenience but by urgent economic and clinical necessity. The Burden of Disease and Economic Inactivity The impetus for the massive growth forecasted for 2026 stems from the sheer scale of the MSK burden. Musculoskeletal conditions are currently the leading cause of disability worldwide, affecting over 1.7 billion people. In the United Kingdom alone, poor musculoskeletal health has emerged as a leading cause of health-related economic inactivity, with an estimated 26.5 million working days lost to these conditions in 2024. This is not merely a clinical statistic but a macroeconomic warning sign; as workforce productivity stagnates, the inability of traditional healthcare systems to manage chronic pain efficiently has become a drag on national GDPs. In the United States, the financial stakes are even higher. MSK disorders affect approximately one in two adults, costing payers and patients an estimated $661 Billion annually.This expenditure is driven largely by a "surgical-first" culture that prioritises high-cost interventions, such as spinal fusions and joint replacements, over conservative management. Data indicates that up to 30% of MSK surgeries may be inappropriately performed and 36% of all MSK surgeries are considered unnecessary. With the average cost of a single lumbar surgery exceeding $22,000, and often ranging significantly higher depending on complications, the economic incentives for "surgery avoidance" technologies have never been stronger. The year 2026 is projected to be a watershed moment because it marks the maturation of digital interventions that can credibly claim to reverse these trends. The market is moving beyond simple "tele-physio" video calls toward comprehensive, AI-driven platforms that integrate preventative care, acute injury management, and post-surgical rehabilitation. By 2025, the global digital MSK care market is estimated to be valued at approximately $5.10 Billion, but this is merely the baseline. Forecasts indicate an acceleration to nearly $16 Billion by 2032, driven by compound annual growth rates (CAGR) exceeding 17%. This growth is structurally underpinned by a shift in payer mentality: insurers and self-insured employers are no longer viewing digital MSK as a "wellness perk" but as a primary mechanism for cost containment and risk management. The "Left Shift" and Systemic Transformation A critical driver for the 2026 growth explosion is the explicit policy objective in major health systems to move care "upstream" and "left", meaning away from hospitals and into the community or home. In the UK, the government's "10 Year Health Plan" and the NHS's strategic focus on moving "from analogue to digital" and "hospital to community" provide the regulatory tailwind for this shift. The goal is to end the "8 am scramble" for GP appointments by empowering patients to self-manage conditions via digital tools integrated into the NHS App. This policy shift creates a fertile environment for digital MSK platforms like getUBetter, which has already achieved adoption across 40% of NHS England's Integrated Care Systems (ICSs). By enabling patients to self-manage common injuries without seeing a GP, these platforms directly alleviate the workforce crisis. With NHS community MSK waiting lists exceeding 388,000 people in August 2025, the traditional system has reached capacity. The "massive growth" predicted for 2026 is, therefore, partly a function of supply-side constraints; without digital scalability, national health systems face collapse in MSK service delivery. Quantitative Market Architecture and Forecasts To understand the magnitude of the opportunity in 2026 and beyond, it is essential to dissect the market sizing data, regional variances, and segmentation trends that define the sector. Global Market Valuation and Growth Vectors The financial projections for the digital MSK market reflect high confidence among analysts, though methodologies vary. The consensus indicates a market entering a "hyper-growth" phase. Global Digital MSK Market Forecasts (2024–2035) Metric Grand View Research Coherent Market Insights Research and Markets Quintile Reports 2024/2025 Valuation ~$4.44 Billion (2024) ~$5.10 Billion (2025) ~$4.53 Billion (2024) ~$6.45 Billion (2025) Future Valuation ~$11.64 Billion (2030) ~$15.92 Billion (2032) ~$26.54 Billion (2035) ~$12.35 Billion (2034) CAGR 17.7% (2025-2030) 17.64% (2025-2032) 17.43% (2025-2035) 18.17% (2025-2034) Key Growth Driver Prevalence of disorders, aging population Telemedicine adoption, cost-effective treatment Wearable tech, AI diagnostics Rapid tech adoption, sustainable practices The data suggests a robust expansion trajectory, with the market expected to nearly triple in value between 2025 and 2032. The consistent CAGR estimates in the high teens (17-18%) across multiple independent reports reinforce the structural nature of this growth. Regional Dominance and Emerging Pockets While North America currently leads the market, holding approximately 40.3% of the revenue share in 2025, the dynamics are shifting. The US market is characterised by high healthcare spending and the dominance of the self-insured employer model, where companies like Hinge Health and Sword Health compete for corporate contracts to lower claims costs. However, the Asia Pacific region is projected to be the fastest-growing market, expected to capture a 35.2% share by 2025. This rapid acceleration is fuelled by the digitalisation of healthcare infrastructure in China and India, alongside the pressing needs of Japan’s super-aged society. In Europe, the United Kingdom represents a significant growth node. The UK digital MSK market is forecast to grow from $194.7 million in 2024 to $526.0 million by 2030, registering a CAGR of 18.2%. This growth outperforms the broader corporate wellness market in the UK, which is expected to grow at a modest 3.8% CAGR over the same period, highlighting that MSK is a specific high-value vertical within the broader health ecosystem. Segment Analysis: Software vs. Hardware The market is bifurcated into hardware (wearables, sensors) and software (apps, platforms). Currently, the Software & Services segment dominates, accounting for approximately 60% of revenue in 2024/2025. This dominance is driven by the scalability of app-based solutions that do not require complex logistics. However, a divergence in forecast exists: while software remains the largest revenue generator, Hardware is identified by some analysts as the fastest-growing component over the forecast period. This is attributed to the increasing sophistication of wearable sensors and diagnostic tools that offer real-time monitoring capabilities, moving beyond simple step-counting to clinical-grade range-of-motion (ROM) analysis. Conversely, other reports suggest that Online/Virtual Consultations will maintain dominance due to the rising accessibility of telemedicine. This tension, between hardware enabled precision and software-enabled scalability—defines the central technological battleground for 2026. Technological Convergence: The 2026 Architecture By 2026, the technological underpinnings of digital MSK care will have evolved from "digitised analog care" (video calls) to "digitally native care" (AI, Computer Vision, VR). The Modality War: Sensors vs. Computer Vision A critical strategic divide exists between providers utilizing physical sensors and those relying on computer vision (CV). Sensor-Based Modalities: Companies like Hinge Health have built their clinical validity on sensor-based biofeedback. By strapping wearable sensors (e.g., Enso) to the patient, these platforms track movement fidelity with high precision. The argument for sensors is data granularity; they can detect subtle shifts in movement that a camera might miss. Hinge Health’s outcomes, including a 3.3x ROI in Medicare populations, are heavily predicated on this hardware-integrated approach. However, hardware introduces friction: devices must be shipped, charged, and paired, creating logistical barriers and higher unit economics. Computer Vision (CV) Modalities: Conversely, Kaia Health and Sword Health are championing computer vision. Kaia’s "Motion Coach" utilizes the user's smartphone camera to track exercise form without peripheral hardware. This "hardware-free" approach significantly lowers the barrier to entry and cost of goods sold (COGS). Crucially, clinical validation studies published in the Journal of Medical Internet Research have demonstrated that Kaia's CV technology is as accurate as physical therapists in suggesting exercise corrections. Sword Health employs a hybrid approach but has increasingly marketed its "lens-less" sensor technology while also leveraging CV for scalability. By 2026, improvements in mobile processing power and camera fidelity will likely tip the scale toward CV solutions for general population management, reserving sensors for high-acuity post-surgical cases. Generative AI and the "AI Therapist" The most transformative technology arriving at maturity in 2026 is Generative AI. Beyond simple chatbots, GenAI is being integrated into the clinical pathway to automate triage, documentation, and even therapy delivery. AI Clinics: Flok Health has launched the first AI-powered physiotherapy clinic in England, approved by the Care Quality Commission (CQC). Using AI video generation, Flok provides "same-day appointments" via an app, where a digital avatar conducts the assessment. Trials in Cambridgeshire showed a 55% reduction in back pain waiting lists and a 44% reduction in wait times for all MSK conditions. This proves that AI can function as a capacity multiplier, freeing up human clinicians for complex cases. Clinical Automation: In Northamptonshire, NHS services are trialing "Magic Notes," an AI tool that listens to consultations and automatically generates clinical summaries. This reduces administrative burden, allowing physiotherapists to focus on patient care. As these tools become standard in 2026, the efficiency gains will drive higher throughput in MSK clinics. Predictive Analytics: Sword Health’s "Predict" engine represents the shift from reactive to proactive care. By analyzing historical claims data and member history, the AI identifies individuals at high risk of unnecessary surgery before they even consult a surgeon. Sword claims this predictive intervention can reduce surgery intent by up to 70%. Virtual Reality (VR) and Immersive Therapeutics VR is transitioning from a gaming technology to a reimbursed medical device. The global AR and VR healthcare market is projected to grow at a CAGR of 24.81% through 2034. In 2025, XRHealth acquired RealizedCare, creating a comprehensive platform that combines immersive VR environments with digital cognitive behavioural therapy (CBT). VR is particularly effective for chronic pain management through "distraction therapy," which re-trains the brain's pain processing pathways. By 2026, VR headsets will likely be standard equipment in pain management clinics and home-based chronic pain programs. The Regulatory Crucible: Compliance as a Moat The regulatory environment in 2026 will no longer be the "Wild West" of early digital health. Strict frameworks in the EU, US, and UK will act as a filter, favouring established players with the resources to navigate complex compliance landscapes. The EU AI Act: A New Global Standard The EU AI Act, fully applicable from August 2, 2026, represents the most significant regulatory disruption in the sector. Under this Act, AI systems used for medical triage or diagnosis are classified as "High-Risk AI Systems". Compliance Obligations: Quality Management Systems (QMS): Providers must implement rigorous QMS to manage risks throughout the AI lifecycle. Data Governance: Training data must be vetted for bias to prevent discriminatory outcomes in healthcare delivery. Conformity Assessments: High-risk systems must undergo third-party conformity assessments by notified bodies. Penalties: Non-compliance can result in fines of up to 3% of global turnover or €15 Million. This regulation creates a substantial "moat" for incumbents like Kaia Health and Sword Health, who have already invested in medical-grade compliance (MDR Class IIa certification). Startups lacking this infrastructure will struggle to enter the European market post-2026. US Reimbursement: The CPT Code Revolution (2026) In the United States, the maturation of Remote Therapeutic Monitoring (RTM) codes is aligning financial incentives with digital care delivery. The Centers for Medicare & Medicaid Services (CMS) have proposed critical updates for the 2026 Physician Fee Schedule that directly address previous limitations. 2026 US CPT Code Landscape for Digital MSK CPT Code Description 2026 Status/Change Strategic Implication 98977 RTM Device Supply (MSK System) Revised (16-30 days) Reimbursement ~$40-47. Continues to support chronic care monitoring requiring steady data streams. 98985 RTM Device Supply (Short-term) NEW (2-15 days) Game Changer: Allows providers to bill for short acute episodes (e.g., rapid post-op recovery) where 16 days of data is unnecessary. Reimbursement ~$40. 24 98980 RTM Treatment Mgmt (First 20 min) Active Reimbursement ~$54. Covers clinician time reviewing AI-generated data insights. 98979 RTM Treatment Mgmt (Short-term) NEW (First 10 min) Flexibility: Allows reimbursement for shorter check-ins (10-19 mins), acknowledging that efficient digital tools reduce required interaction time. 24 98975 Initial Setup & Education Active Reimbursement ~$21. Covers the cost of onboarding patients to the app/device. The introduction of codes 98985 and 98979 solves a critical misalignment. Previously, if a patient recovered quickly (in less than 16 days), the provider lost revenue because they couldn't bill the device code. The new codes incentivise efficiency , rewarding providers for rapid recoveries—a perfect fit for effective digital MSK interventions. UK Frameworks: DTAC and the NHS App In the UK, the Digital Technology Assessment Criteria (DTAC) is the non-negotiable gateway for NHS adoption. It evaluates clinical safety, data protection, technical security, interoperability, and usability. Clinical Safety: Apps must employ a Clinical Safety Officer and demonstrate risk management. Integration: Successful platforms like getUBetter have integrated directly into the NHS App, allowing patients to access prescribed digital therapeutics via their primary health interface.The NHS App is transitioning to a "digital front door," where patients can self-refer to MSK services, view care plans, and book appointments. Interoperability: The focus on the Federated Data Platform means apps must be able to write data back to the patient's record, moving beyond siloed ecosystems. Clinical Validity and the ROI Landscape As the market matures, the sales pitch has shifted from "employee wellness" to "hard dollar ROI." Claims reduction is the primary metric for 2026. The ROI Battleground: Hinge vs. Sword The two market leaders, Hinge Health and Sword Health, are engaged in a fierce battle to prove superior economic outcomes. Hinge Health: Hinge's validity rests on its massive scale. A claims-based study across 136 employers demonstrated a 2.4x ROI. The study compared members to a control group and found a $2,387 reduction in MSK medical claims per participant in the first year. Drivers of Savings: The primary driver was a 39% reduction in surgery-related claims. Savings were also realised in reduced imaging and injections. Medicare Impact: In a separate study of older adults, Hinge demonstrated an even higher 3.3x ROI($3,289 savings per member), proving efficacy in complex, age-related conditions. Sword Health: Sword Health counters with a higher claimed ROI of 3.2x ($3,177 savings per member), a figure they state is "independently validated" by Risk Strategies Consulting. Business Model Innovation: Sword has pioneered 100% risk-based pricing. They only charge fees if the patient achieves defined clinical outcomes. This puts their revenue at risk but signals extreme confidence in their product. Comparison: Sword explicitly markets against Hinge, claiming their "Digital Physical Therapist" (vs. Hinge's health coaches) leads to better outcomes and that Hinge's ROI is lower. Omada Health: Omada, primarily known for metabolic health, has entered the MSK space with a focus on "Joint & Muscle Health." Their data shows a 1.8x ROI and median savings of over $1,000 per member.33 While their ROI multiple is lower, their advantage lies in the "whole person" platform, managing diabetes and MSK co-morbidities simultaneously. Clinical Outcomes vs. Economic Necessity The data indicates that "surgery avoidance" is the single most valuable metric. With spinal fusions and joint replacements costing tens of thousands of dollars, preventing even a small fraction of these procedures justifies the cost of the entire digital program. Sword Health’s "Predict" engine specifically targets this by identifying "high-risk" members, those likely to spiral into surgery and intervening with aggressive conservative care. Payer and Corporate Adoption Strategies The buyer landscape has evolved from experimental pilots to strategic, wide-scale deployments. Corporate Wellness and "Point Solution Fatigue" Employers are overwhelmed by the number of digital health apps. This "point solution fatigue" is driving consolidation. In 2026, standalone MSK apps will increasingly be purchased through aggregators like Personify Health (formerly Virgin Pulse) or Wellhub. Travis Perkins Case Study: This UK construction giant (20,000+ colleagues) integrated digital wellbeing tools alongside a network of 250+ Mental Health First Aiders. Their approach highlights the need for apps to sit within a broader ecosystem of support, including Employee Assistance Programs (EAPs) and financial wellbeing tools. Barclays Case Study: Legal pressures are also driving adoption. A tribunal ruling against Barclays regarding "reasonable adjustments" for an employee with a chronic condition underscores the legal risk of failing to support employee health. Digital tools provide a scalable, auditable way to demonstrate support for chronic MSK conditions in the workplace. The Insurance Sector: From Payer to Partner Insurers are shifting from passively paying claims to actively managing health via tech partnerships. Vitality Health & Google: Vitality has partnered with Google Cloud to launch "Vitality AI." This platform uses Google's Gemini models to analyse member data (health, lifestyle, clinical risk) and generate hyper-personalised recommendations. Goal: To extend healthy life expectancy and reduce claims. Vitality data shows that personalised screening can increase cancer detection rates by 19%. This partnership signals that Big Tech (Google) views the insurance layer as the ideal distribution channel for its health AI. UK Private Medical Insurance (PMI): Aviva: Offers a "BacktoBetter" pathway that allows members to access MSK case management without a GP referral. Members can use the Aviva Digital GP app to get a referral to a physiotherapist, bypassing NHS waiting lists entirely. AXA vs. Bupa: Both major insurers have integrated digital GP services (AXA's "Doctor at Hand" vs. Bupa's "Digital GP"). However, they differentiate on coverage nuances. AXA is noted for flexible outpatient options and keen pricing, while Bupa offers extensive network access and comprehensive cancer cover. Both utilise digital triage to steer patients toward the most cost-effective care pathway, often digital physio. Workforce Transformation: The Physiotherapy Crisis The "massive growth" of digital MSK is also a response to a breaking point in the human workforce. The Supply-Demand Mismatch The UK is facing a severe shortage of physiotherapists. The Chartered Society of Physiotherapy (CSP) reports that 74% of NHS physiotherapists have experienced a decline in the quality of rehabilitation they can offer due to lack of space and resources. NHS waiting lists for MSK care are rising month-on-month. TechUK's Assessment: A survey of digital health professionals found that 96% believe workforce pressures are preventing digital progress, yet 60% feel unprepared to deliver on the NHS's digital ambitions. Digital as the Only Viable Solution In this context, digital platforms are not "replacing" physios but "saving" the service. Capacity Release: Platforms like getUBetter reduce GP follow-up appointments by 13% and physiotherapy referrals by 20%. This "releases" human capacity to focus on complex patients who genuinely need hands-on care. Hybrid Workforce: The future workforce will be hybrid. The CSP is advocating for "clinical informaticians" and digital leadership roles within physiotherapy. By 2026, a physiotherapist's job description will include managing a "digital caseload" of patients monitored via AI, alongside their in-person clinic list. Strategic Conclusion As we look toward 2026 and beyond, the Digital MSK market is not merely "growing"; it is becoming the structural foundation of modern orthopedic care. The convergence is complete: Generative AI provides the intelligence, Computer Vision provides the accessibility, New CPT Codes provide the financial incentive, and the EU AI Act provides the safety guardrails. The winners in this new era will be the platforms that can seamlessly integrate into the "phygital" workflow, triaging patients via an app, treating the 50-70% of simple cases digitally, and intelligently routing complex cases to human surgeons and therapists. For employers and payers, the question is no longer "Should we offer digital MSK?" but "Which partner offers the most rigorous, risk-adjusted ROI?" In a world of rising costs and aging populations, digital MSK has graduated from a novelty to a necessity. Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk   Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @   https://www.healthcare.digital     We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb     Founders for Founders >  We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk   #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #BuySide   #SellSide #Divestitures   #Corporate   #Portfolio   #Optimisation   #SeriesA   #SeriesB   #Founders   #SellSide   #TechAssets   #Fundraising #BuildBuyPartner   #GoToMarket   #PharmaTech   #BioTech   #Genomics   #MedTech   Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk   Meet Us @ HealthTech events   October 2025 Healthcare Summit 2025, London, UK – Chairing the HealthTech M&A Panel Healthcare Summit 2025, London, UK – Chairing the HealthTech Deal Structuring Panel NHS Clinical Entrepreneur Conference, Belfast, Northern Ireland Global Health Exhibition 2025, Riyadh, Saudi Arabia – Chairing the HealthTech M&A Panel November 2025 HealthTech X Summit, London, UK – Chairing the “HealthTech predictions for 2026” Panel MedTech Europe 2025, Valletta, Malta- Speaker on the "Startups, Corporates & Hospitals: How to Build Meaningful MedTech Partnerships" panel MedTech Europe 2025, Valletta, Malta- Judge for the MedTech StartUp Pitch Awards Leaders in Health Summit 2025 December 2025 HealthTech Forward 2025, Barcelona, Spain – Moderating the Health Data Under Attack” Panel Healthcare Club, IESE Business School, Barcelona, Spain HealthInvestor Power List Awards 2025, London, UK – Judging Panel Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk

Who are the leading boutique investment banks advising European Digital Health founders and Venture Capital funded companies? Executive Summary: The Structural Transformation of HealthTech Capital Markets The European Digital Health and HealthTech landscape is currently navigating a period of profound structural transformation, transitioning from the liquidity-fueled exuberance of the post-pandemic era into a disciplined, metric-driven environment characterized by a "flight to quality". This report offers an analysis of the investment banking and strategic advisory ecosystem supporting European founders, Venture Capital (VC) funds, and Private Equity (PE) firms through this complex transition. As the market matures, a bifurcated advisory landscape has emerged. While global "bulge bracket" institutions such as Goldman Sachs and J.P. Morgan continue to dominate mega-cap transactions and large-scale pharmaceutical consolidations, a highly specialized tier of boutique investment banks has established itself as the primary architect of the mid-market ecosystem. These specialised firms, most notably Nelson Advisors, Clipperton, Arma Partners and Lincoln International, have carved out defensible market positions by offering domain specific expertise that generalist firms cannot replicate. The strategic imperative for specialised advisory has never been more acute. Valuations in 2024 and 2025 are no longer driven by growth-at-all-costs narratives but are instead anchored in unit economics, clinical validation and the strategic integration of Artificial Intelligence (AI) into clinical workflows. Consequently, the role of the investment banker has evolved from a transactional facilitator to a strategic partner capable of bridging the linguistic and valuation gaps between agile, tech-centric founders and risk-averse, clinically focused acquirers. This report explores the nuances of this evolving landscape, providing deep profiles of the key advisory players, analysing the macroeconomic drivers shaping deal flow, and offering a forward-looking perspective on the European HealthTech M&A horizon. The Macro-Strategic Environment for European HealthTech M&A (2024-2025) The Valuation Paradigm Shift: From Revenue to Profitability The investment climate governing European HealthTech has undergone a decisive pivot. During the zero-interest-rate policy (ZIRP) era, valuations were frequently pegged to aggressive forward-revenue multiples, often ignoring underlying profitability. However, the current environment is defined by a rigorous focus on sustainable growth and EBITDA metrics. Data from 2024 and projections for 2025 indicate that while general deal volumes have seen fluctuations, high-quality assets, defined by recurring revenue, low churn, and proven clinical utility, continue to command premium valuations. For HealthTech specifically, Enterprise Value (EV) to revenue multiples have stabilized in the 4x-6x range for high-growth companies. In contrast, profitable entities with established market positions are seeing EV/EBITDA multiples in the 10x-14x range, reflecting a cautious but persistent optimism in the market. This shift necessitates a new breed of financial advisor: one who can articulate a "path to profitability" narrative effectively while defending valuation premiums based on technological defensibility rather than mere user growth. The AI Premium and the Regulatory Moat Artificial Intelligence has emerged as the single most significant differentiator in valuation discussions. Companies possessing proprietary, clinically validated AI algorithms, particularly in diagnostics, drug discovery and predictive analytics, are commanding significant premiums, often breaking the standard multiple ceilings. However, this "AI Premium" is increasingly contingent upon regulatory compliance. The implementation of the EU AI Act in August 2024 has introduced a layer of complexity to the due diligence process that generalist advisors are often ill-equipped to handle. Health AI systems frequently fall under the "High-Risk" category of the Act, mandating rigorous governance, transparency, and data validation. Acquirers are no longer simply purchasing code; they are acquiring compliance ready infrastructure. This development has elevated the importance of specialised advisors who understand the intersection of deep tech and medical regulation, as the ability to audit these risks during pre-sale preparation has become a critical determinant of deal success. The Strategic Bifurcation of the Advisory Landscape The analysis suggests a clear segmentation in the advisory landscape, driven by the diverging needs of different company stages and acquirer profiles: The Mega-Cap Generalists: Firms like Goldman Sachs, Rothschild & Co, and J.P. Morgan lead by value and volume in the large-cap space. They are essential for multi-billion dollar transformative deals, often involving global pharmaceutical giants or massive cross-border mergers. Their value proposition lies in their unparalleled access to global capital markets and their ability to finance mega-deals. The Tech-Centric Scale Players: Firms like Arma Partners and GP Bullhound leverage their massive software deal flow to apply technology valuations to healthcare assets. They view health deals primarily through the lens of the "Digital Economy," focusing on SaaS metrics and software scalability. The Specialist Boutiques: Firms like Nelson Advisors and Clipperton offer highly targeted, domain-specific expertise. They often cater to founder-led exits and specific verticals like Health IT, MedTech, and AI, providing a level of operational empathy and sector nuance that larger firms cannot provide. Deep Dive: Nelson Advisors – The "Founders for Founders" Archetype Among the boutique advisors serving the European market, Nelson Advisors stands out for its distinct "Founders for Founders" operational model. Unlike traditional investment banks staffed by career financiers, Nelson Advisors is led by individuals who have successfully built, scaled and exited their own HealthTech ventures. This operational DNA allows them to align closely with the mindset of entrepreneurs and early-stage investors who are navigating the complexities of their first major liquidity events. Leadership and Operational DNA The firm’s credibility is anchored in the track records of its founding partners, Lloyd Price and Paul Hemings, whose combined experience bridges the gap between high-level corporate finance and the gritty reality of startup execution. Lloyd Price (Co-Founder & Partner) Lloyd Price is a central figure in the UK and European digital health scene, bringing over 25 years of experience to the firm. His background is unique in that it spans consumer internet (Yahoo, Kelkoo) and deep HealthTech, giving him a rare ability to translate consumer engagement metrics into healthcare valuations, a critical skill in the B2C2B (Business-to-Consumer-to-Business) health market. Entrepreneurial Track Record: Price co-founded Zesty, a patient engagement platform, and successfully guided it to an exit in 2020 when it was acquired by Induction Healthcare Group PLC(FTSE: INHC). This direct experience of selling a company to a public entity provides him with an intimate understanding of the pressures founders face during due diligence and negotiation. Thought Leadership: Price serves as a Health Executive in Residence at the UCL Global Business School for Health, cementing his academic and strategic influence. He is frequently cited as an expert on the "AI Premium" and the intersection of consumer technology and clinical pathways, and he actively judges prestigious industry awards such as the HealthInvestor Power List, Digital Health PitchFest, and HLTH Europe Awards. This visibility ensures Nelson Advisors remains at the forefront of emerging trends and maintains deep networks within the founder community. Paul Hemings (Co-Founder & Partner) Paul Hemings complements Price’s operational background with extensive corporate finance expertise. Financial Expertise: Hemings brings over a decade of global M&A and capital raising expertise, having held senior investment banking advisory roles at Credit Suisse. His transaction experience encompasses over $50 billion in M&A and $40 billion in equity and financing transactions across a vast international footprint, including the US, UK, Europe, and Asia. Entrepreneurial Experience: Hemings also possesses direct entrepreneurial experience, having co-founded Neutrally, a venture focused on chronic lifestyle disease and metabolic health. This background allows him to offer institutional-grade financial structuring while maintaining the agility and empathy of a startup advisor. Strategic Focus and Deal Sweet Spot Nelson Advisors focuses primarily on the Lower Mid-Market ($25M - $250M). This segment is critical for Venture Capital exits, often representing the Series A or Series B stage where a trade sale becomes a viable and attractive alternative to further dilution or a stalled IPO track. The firm’s specialisation covers several high-growth verticals: Healthcare AI & Cybersecurity: Recognizing the critical nature of data integrity and algorithmic validation, Nelson Advisors has carved out a niche in advising companies that operate at the intersection of healthcare and security. This is particularly relevant given the increasing frequency of cyberattacks on healthcare infrastructure and the stringent requirements of the EU AI Act. Digital Health & Telehealth: The firm has deep expertise in patient engagement, remote care models, and digital therapeutics, leveraging Price’s experience with Zesty to advise next-generation platforms. Tech Asset Sales & Corporate Divestitures: Nelson Advisors assists larger entities in shedding non-core assets to optimize portfolios. This "Corporate Divestiture" service helps clients shed lower-growth businesses and liberate capital for reinvestment in higher-growth, strategically aligned areas. The "Build, Buy, Partner, Sell" Framework Nelson Advisors employs a "Build, Buy, Partner, Sell" strategic framework, which distinguishes it from purely transactional brokers. This consultative approach involves engaging with clients early in their lifecycle, often years before a sale, to determine the optimal strategic path for maximising shareholder value. Build: Advising on internal growth strategies and product-market fit. Buy: Assisting with "roll-up strategies" where clients acquire smaller companies to build a larger, more dominant entity before seeking an exit. Partner: Facilitating channel partnerships and joint ventures that can drive revenue growth and validate technology without immediate equity dilution. Sell: Executing the final exit transaction, whether to a strategic acquirer or a financial sponsor. Market Intelligence and Thought Leadership Nelson Advisors leverages its thought leadership as a core business development tool. The firm publishes the "HealthTech M&A" newsletter on LinkedIn, which provides weekly analysis of major European and North American transactions, valuation multiples, and sector-specific deep dives. This consistent output establishes the firm as a knowledge hub for the industry, attracting inbound interest from founders and investors alike. Their recent analysis on "HealthTech M&A Multiples in 2025" and the "UK HealthTech M&A Landscape" has been widely referenced, providing transparency in a market that is often opaque. Deep Dive: Lincoln International – The Global Connector Lincoln International is a global mid-market investment bank with a reputation for deep vertical expertise and a "relationship-driven" advisory model. In the healthcare sector, they are particularly strong in Healthcare Services, Provider IT, and Aged Care. They often handle deals that involve a mix of technology and service delivery, effectively bridging the gap between pure tech and traditional healthcare provision. The Global Industry Group Model Lincoln operates with a strong UK/DACH (Germany, Austria, Switzerland) axis, which is critical given that the DACH region is one of the largest healthcare markets in Europe. Their "Global Industry Group" model ensures that a client in Germany has seamless access to buyers in Chicago or Tokyo, leveraging the firm's physical presence in key global financial hubs. Convergence of IT and Services Lincoln excels in advising on deals where the line between "Healthcare Services" and "Healthcare IT" is blurred. Fresh Tandartsen: Lincoln advised Livingbridge on the sale of this Dutch dental group to European Dental Group (a portfolio company of Nordic Capital). While primarily a services deal, the consolidation of dental practices is increasingly driven by the integration of practice management software and digital imaging technologies, areas where Lincoln's dual expertise adds significant value. Curium Recapitalisation: Lincoln advised CapVest on the $7 Billion recapitalisation of Curium, a world leader in nuclear medicine. This transaction demonstrates their ability to handle massive, complex life sciences transactions alongside digital health deals, providing a "full-spectrum" service to healthcare clients. Data-Driven Insights: The Private Market Index Lincoln differentiates itself with its Lincoln Private Market Index (PMI), which tracks changes in the enterprise values of privately held companies. This proprietary dataset allows them to provide clients with real-time valuation benchmarks that are more accurate than public market comps, which can be volatile and less representative of mid-market assets. In Q4 2024, the PMI showed that European private companies significantly outperformed public ones, a data point that Lincoln bankers use to encourage private market transactions. The Merchant Banking & Investment Model: GP Bullhound GP Bullhound operates as both an advisory firm and an investor (via its venture funds), giving it a "skin in the game" perspective similar to Nelson Advisors but on a larger scale. They focus heavily on "Category Leaders" and potential unicorns, often blurring the lines between advisor and investor. The "Unicorn Hunter" Strategy GP Bullhound has a reputation for identifying and backing technology companies that have the potential to reach billion-dollar valuations. Flo Health: A standout transaction in 2024 was advising Flo Health, a consumer women's health app, on its $200 million investment from General Atlantic. This deal propelled Flo Health to unicorn status and exemplifies GP Bullhound's strength in B2C (Business-to-Consumer) digital health, a segment that many B2B-focused advisors avoid due to its higher risk profile and reliance on consumer marketing metrics. The Investor-Advisor Hybrid GP Bullhound’s venture capital arm invests in many of the sectors it advises on. This "Merchant Banking" model allows them to support companies through multiple stages of growth, from Series B investment to eventual exit. While this can create potential conflicts of interest, it also aligns the firm’s incentives with the long-term success of the founder. Their investment in companies like Mentimeter and RavenPack demonstrates their active participation in the broader tech ecosystem. Thought Leadership and Events GP Bullhound is renowned for its high-profile events, such as the Northern Tech Awards and the Allstars Awards, which serve as major networking hubs for the European tech elite. Their annual "Technology Predictions" report is widely read and influences market sentiment regarding emerging trends like consumer subscription software in health. Transatlantic Convergence: The Stifel / Bryan Garnier Case A major market development that has reshaped the advisory landscape is the acquisition of Bryan Garnier & Co by Stifel Financial Corp, a process that concluded in mid-2025. This consolidation represents a significant shift towards transatlantic integration in the middle market. Creating a Transatlantic Powerhouse Bryan Garnier was previously a leading independent European boutique known for its expertise in growth tech and healthcare. By merging with Stifel, a US-based mid-market heavyweight, the combined entity creates a platform that offers European founders immediate and seamless access to US capital markets. Strategic Rationale: The merger addresses the "scale-up gap" often faced by European companies, which struggle to raise large growth rounds compared to their US peers. The combined firm can now offer a full suite of services, including NASDAQ IPOs, US institutional private placements, and cross-border M&A execution, all under one roof. Leadership Continuity: Olivier Garnier, co-founder of Bryan Garnier, now serves as Chairman of Stifel Europe, ensuring that the firm retains its entrepreneurial DNA and deep European relationships while leveraging Stifel's massive distribution network. Emerging and Regional Players Beyond the primary boutique leaders, several other firms play critical roles in specific niches of the European Digital Health ecosystem. WG Partners: The Life Sciences Specialists WG Partners, led by Nigel Barnes and Claes Spång, is distinct in its focus on the Life Sciences and Biotech end of the spectrum. They specialize in capital raising (public and private) and corporate advisory for companies that may have a heavier R&D or clinical trial component than a pure SaaS health player. They are essential for "Bio-IT" convergence companies that sit between digital health and traditional biotech, helping them structure equity stories for public markets. Clearwater International: Mid-Market Execution Clearwater International is a volume leader in the mid-market, particularly strong in private equity transactions. Their healthcare team won "Corporate Financier of the Year" at the 2024 HealthInvestor Awards, a testament to their execution capability. Buy-and-Build Strategy: Clearwater is known for executing "buy-and-build" strategies for PE-backed platforms. Their deep regional coverage across Europe (France, UK, Scandinavia) allows them to identify "off-market" targets for consolidation, facilitating the growth of pan-European healthcare groups. The VC Ecosystem and Exit Dynamics The relationship between Venture Capital funds and investment banks is symbiotic. As VC funds reach the end of their investment cycles, they rely on these specialised banks to engineer exits that return capital to Limited Partners (LPs). The "Take-Private" Wave A significant trend influencing the advisory landscape is the surge in "Take-Private" transactions. Public markets in 2023 and 2024 wilted under interest rate pressures, leaving many high-quality European HealthTech companies undervalued relative to their private counterparts. This has sparked a wave of acquisitions by Private Equity firms looking to arbitrage this valuation gap. Advisors with strong leveraged finance teams and deep relationships with sponsors like EQT, KKR, and Apax are gaining market share in this arena. Secondary Markets and Continuation Vehicles With the IPO window remaining constrained, advisors are increasingly working on secondary transactionsand continuation vehicles. These mechanisms allow VC funds to achieve partial liquidity without a full exit. Firms like Arma Partners and Clipperton are active in structuring these complex deals, which require a deep understanding of fund dynamics and LP requirements. Comparative Analysis of Leading Boutique Advisors The following table summarises the key differentiators, focus areas, and strategic strengths of the leading boutique advisors analysed in this report. Advisory Firm Primary Persona Deal Size Focus Key Differentiators Strategic Strength Nelson Advisors "The Entrepreneurial Architects" Lower Mid-Market ($25M - $250M) Founder-led (Lloyd Price, Paul Hemings), deep operational DNA, "Founders for Founders" model. Navigating early VC exits, AI & Cybersecurity focus, "Build/Buy/Partner/Sell" long-term strategy. Clipperton "The Research-Led Tech Specialists" Mid-Market "Dual Advisory" (Tech + Health), extensive proprietary research (Health Tech Monitor). Cross-border SaaS metrics applied to health, newly launched Debt Advisory capability. Arma Partners "The Digital Economy Heavyweights" Mid-to-Large Cap ($100M - $1B+) Massive scale ($58bn deal vol), deep software expertise, US/Asian reach. Connecting European assets to global capital, large-scale PE recapitalisations, "Platform" deals. Lincoln International "The Global Connectors" Global Mid-Market Relationship-driven, deep Healthcare Services & IT expertise, Global Industry Groups. Global footprint with strong local DACH/UK presence, hybrid service/tech deals, Private Market Index data. GP Bullhound "The Unicorn Hunters" Growth / Late Stage Investor-Advisor hybrid model, consumer-tech focus. B2C Digital Health, high-profile "unicorn" rounds (e.g., Flo Health), strong marketing/events ecosystem. Clearwater Int. "The PE Execution Machine" Mid-Market High volume of PE deals, award-winning healthcare team. Buy-and-build strategies, deep regional pan-European coverage, "off-market" sourcing. Future Outlook (2025-2026) The European Digital Health investment banking landscape for 2025 and 2026 is defined by specialised expertise. The era of the generalist banker serving the digital health founder is largely over for the mid-market. The complexity of AI regulation, the nuance of SaaS-in-Healthcare valuations, and the specific needs of VC-backed exits require advisors with deep domain knowledge. Key Trends to Watch: Selectivity is Key: Founders must align their choice of advisor with their company stage. Nelson Advisors is best suited for the founder-led, early-exit demographic ($25M-$200M) where operational empathy is crucial. Arma Partners is the go-to for mature, pan-European platforms looking for billion-dollar exits or recapitalisations. The AI Mandate: Advisors who cannot competently discuss the regulatory and technical moat of AI algorithms (and the impact of the EU AI Act) will struggle to close deals. The ability to audit and present AI assets is now a core banking competency, favouring firms like Nelson Advisors and Clipperton that have invested in this expertise. Convergence Continues: The acquisition of Bryan Garnier by Stifel and the growth of transatlantic deal corridors suggest that European digital health is becoming increasingly integrated with US capital markets. Advisors with a "transatlantic bridge" capability will drive the highest value outcomes in 2025 and beyond. In conclusion, the leading boutique investment banks are playing a pivotal role in maturing the European HealthTech ecosystem. By providing sophisticated, sector-specific advice, they are helping to turn promising startups into sustainable, compliant, and valuable platforms that will define the future of healthcare delivery in Europe. Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events October 2025 Healthcare Summit 2025, London, UK – Chairing the HealthTech M&A Panel Healthcare Summit 2025, London, UK – Chairing the HealthTech Deal Structuring Panel NHS Clinical Entrepreneur Conference, Belfast, Northern Ireland Global Health Exhibition 2025, Riyadh, Saudi Arabia – Chairing the HealthTech M&A Panel November 2025 HealthTech X Summit, London, UK – Chairing the “HealthTech predictions for 2026” Panel MedTech Europe 2025, Valletta, Malta- Speaker on the "Startups, Corporates & Hospitals: How to Build Meaningful MedTech Partnerships" panel MedTech Europe 2025, Valletta, Malta- Judge for the MedTech StartUp Pitch Awards Leaders in Health Summit 2025 December 2025 HealthTech Forward 2025, Barcelona, Spain – Moderating the Health Data Under Attack” Panel Healthcare Club, IESE Business School, Barcelona, Spain HealthInvestor Power List Awards 2025, London, UK – Judging Panel MedTech Innovator Awards - Judge Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

This Week in European HealthTech and MedTech: 12th December 2025 European HealthTech this week is dominated by EU-level moves to unlock health data for AI, ongoing NHS digital transformation in the UK, and continued momentum around EU‑wide digital health initiatives and summits.​ EU data and AI rulebook The European Commission’s proposed “Digital Omnibus” package includes a “Data Unlock” concept, adjusting GDPR and related digital laws to enable broader secondary use of health data for AI training under strict safeguards. This is paired with a wider “Digital Fitness Check” and timelines that link future high‑risk AI health applications to availability of harmonised standards, with long‑stop dates into 2027–2028 for full compliance.​ EU digital health strategy and events The European Digital Health Summit in Madrid (1–2 December) focused on the European Health Data Space, cross‑border EHR interoperability and a “One Health” approach, highlighting that governance and access rules, rather than technology, are now the key bottlenecks. Fresh Commission communication this week also underlines that all EU countries now provide electronic health record access and are investing in e‑prescriptions, AI integration and digital governance as levers for productivity and resilience.​ NHS and UK digital initiatives In the UK, a new reference guide from NHS Confed and national digital programmes detail up to £10 billion in committed NHS tech and digital transformation spend by 2028/29, with priorities around the NHS App, virtual wards, AI infrastructure and standardised use of wearables. The wider UK digital health strategy emphasises the NHS App as the “front door” to services, integration of consumer wearables into a single patient record, and expansion of AI‑powered tools for advice, triage and service comparison.​ Care, productivity and social care digitisation The UK government reported that four in five care providers now use digital social care records, covering nearly 90% of people drawing on care, and framed this as a key driver of administrative time savings and better data sharing with NHS services. Independent analysis of NHS productivity this month links digital tools, including electronic records and decision‑support, to the system’s ambition of 2% annual productivity growth in the medium term.​ Ecosystem signals and funding Weekly European startup funding round‑ups continue to show steady but selective capital deployment into verticalised AI and digital health infrastructure, with HealthTech deals featuring among broader tech raises across the continent. EU‑funded initiatives such as EDiHTA are being showcased in Commission‑backed webinars to demonstrate how projects support digital health transformation and to feed recommendations into future EU policy and reimbursement frameworks. >>> European MedTech this week is defined by three themes: regulatory moves around data and devices, imaging and diagnostics innovation (largely via RSNA spillover), and fresh capital forming for growth-stage and infrastructure-heavy plays in Europe.​ Regulation and policy The European Commission’s emerging “Digital Omnibus” package includes a proposed “Data Unlock” that would ease the secondary use of health data for AI training under GDPR, with significant implications for MedTech and imaging AI developers.​ The Commission also published updated material on medical device availability monitoring and implementation of MDR/IVDR, signalling continued pressure on supply, data collection on market gaps, and further tweaks to the device rulebook through 2025–2026.​ Imaging, AI and platforms At RSNA 2025, European majors such as Siemens Healthineers and Philips pushed next‑generation MRI and CT platforms emphasising energy efficiency and deeply embedded AI (for example, AI‑native spectral CT and interventional MRI workflows), reinforcing Europe’s strength in high-end imaging hardware plus software.​ GE HealthCare’s roughly 2.3 billion dollar acquisition of imaging IT vendor Intelerad, while US‑led, is highly relevant for European providers because it consolidates PACS/VNA and advanced imaging software into a tighter GE ecosystem that will compete more directly with incumbents like Agfa and Sectra across EU hospitals.​ Capital flows and M&A Angelini Ventures and the European Investment Bank formally committed a 150 million euro co‑investment vehicle (75 million euros each) aimed at European biotech and MedTech scale‑ups, explicitly targeting the Series B “valley of death” that often pushes founders toward US buyers.​Broader MedTech M&A commentary for 2025 highlights continued strategic consolidation in areas such as ophthalmology clinics and robotics, with Europe remaining a core geography for clinic networks and surgical technology platforms seeking scale and integrated care models.​ Events and ecosystem signals MedTech Europe is preparing its annual value‑based procurement conference in Brussels (9 December), keeping reimbursement, outcomes-based contracting, and hospital procurement reform high on the agenda for device manufacturers selling into EU health systems. Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk   Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @   https://www.healthcare.digital     We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb     Founders for Founders >  We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk   #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #BuySide   #SellSide #Divestitures   #Corporate   #Portfolio   #Optimisation   #SeriesA   #SeriesB   #Founders   #SellSide   #TechAssets   #Fundraising #BuildBuyPartner   #GoToMarket   #PharmaTech   #BioTech   #Genomics   #MedTech   Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk   Meet Us @ HealthTech events   October 2025 Healthcare Summit 2025, London, UK – Chairing the HealthTech M&A Panel Healthcare Summit 2025, London, UK – Chairing the HealthTech Deal Structuring Panel NHS Clinical Entrepreneur Conference, Belfast, Northern Ireland Global Health Exhibition 2025, Riyadh, Saudi Arabia – Chairing the HealthTech M&A Panel November 2025 HealthTech X Summit, London, UK – Chairing the “HealthTech predictions for 2026” Panel MedTech Europe 2025, Valletta, Malta- Speaker on the "Startups, Corporates & Hospitals: How to Build Meaningful MedTech Partnerships" panel MedTech Europe 2025, Valletta, Malta- Judge for the MedTech StartUp Pitch Awards Leaders in Health Summit 2025 December 2025 HealthTech Forward 2025, Barcelona, Spain – Moderating the Health Data Under Attack” Panel Healthcare Club, IESE Business School, Barcelona, Spain HealthInvestor Power List Awards 2025, London, UK – Judging Panel MedTech Innovator Awards - Judge Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk

PitchFest Awards at Digital Health ReWired 2026: Nelson Advisors invited to the Judges Panel Nelson Advisors Partner Lloyd Price has been invited to Judge the PitchFest Awards at ReWired 2026. This is the third time Lloyd has judged the prestigious awards, highlighting the pedigree of UK Digital Health and MedTech companies. Unlike standard "demo days," PitchFest is specifically designed to break down the barriers between start-ups and the NHS. The judges are not just venture capitalists but also Chief Information Officers (CIOs) and Chief Clinical Information Officers (CCIOs) who have the actual authority to procure new technology for hospitals. PitchFest Awards at ReWired 2026 The PitchFest Awards at ReWired 2026 is the final stage of the UK's most high-profile digital health start-up competition, organised as part of the annual Digital Health Rewired conference and exhibition.  It  provides a platform for innovators to pitch their solutions to influential leaders, investors, and NHS digital teams. The competition follows a phased process to select the final winners: Application: Start-ups submit their proposals. The deadline for 2026 applications is 21 November 2025. Virtual Heats: Shortlisted contestants pitch their solutions virtually to a panel of judges from the NHS, venture capitalists, and digital health accelerators. Live Final: The top finalists compete live on stage at the Rewired conference. https://digitalhealthrewired.com Winner's Prize The winners receive significant support and exposure, most notably: Pilot Opportunity: Expert advice and the potential to run a real-world project within the Chelsea and Westminster Hospital NHS Foundation Trust, delivered through the CW Innovation Team and Pitchfest partner CW+. Visibility: Free entry to Rewired 2026 and features on Digital Health News. The competition often includes separate categories for pre-revenue and revenue-generating start-ups. Past winners have achieved significant growth and secured funding within the NHS and international markets. https://digitalhealthrewired.com/pitchfest Digital Health ReWired 2026 >> Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk   Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @   https://www.healthcare.digital     We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb     Founders for Founders >  We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk   #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #BuySide   #SellSide #Divestitures   #Corporate   #Portfolio   #Optimisation   #SeriesA   #SeriesB   #Founders   #SellSide   #TechAssets   #Fundraising #BuildBuyPartner   #GoToMarket   #PharmaTech   #BioTech   #Genomics   #MedTech   Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk   Meet Us @ HealthTech events   October 2025 Healthcare Summit 2025, London, UK – Chairing the HealthTech M&A Panel Healthcare Summit 2025, London, UK – Chairing the HealthTech Deal Structuring Panel NHS Clinical Entrepreneur Conference, Belfast, Northern Ireland Global Health Exhibition 2025, Riyadh, Saudi Arabia – Chairing the HealthTech M&A Panel November 2025 HealthTech X Summit, London, UK – Chairing the “HealthTech predictions for 2026” Panel MedTech Europe 2025, Valletta, Malta- Speaker on the "Startups, Corporates & Hospitals: How to Build Meaningful MedTech Partnerships" panel MedTech Europe 2025, Valletta, Malta- Judge for the MedTech StartUp Pitch Awards Leaders in Health Summit 2025 December 2025 HealthTech Forward 2025, Barcelona, Spain – Moderating the Health Data Under Attack” Panel Healthcare Club, IESE Business School, Barcelona, Spain HealthInvestor Power List Awards 2025, London, UK – Judging Panel Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk

Nelson Advisors invited to Chair the 'Health Data Under Attack: Emerging Vulnerabilities in Healthcare' Panel at Health Tech Forward 2025 Nelson Advisors Partner Lloyd Price Chaired the 'Health Data Under Attack: Emerging Vulnerabilities in Healthcare panel' at Health Tech Forward 2025 in Barcelona this week. The  panel focused around 5 main questions debated by the guests Laura, Alberto and Naoufal. 1) Laura Busquet Raich, Head of Data Protection and ComplianceConsorci de Salut i Social de Catalunya 2) Alberto Pedrouzo Ulloa, Universidade de VigoatlanTTic, Universidade de Vigo 3) Naoufal Elazzouzi, Research Engineer, Gradiant Health Data Under Attack: Emerging Vulnerabilities in Healthcare 1. How does the "Legacy Debt" of healthcare infrastructure compromise modern healthcare cyber security?  Healthcare organisations often layer new digital tools over outdated technical foundations. This question for the panel explored the friction between the need for innovation and the reality of aging systems that were never designed for today's threat landscape  2. How is the definition of "Patient Safety" evolving to include Cyber-Resilience?  This theme shifts the narrative from "data privacy" (protecting the record) to "patient safety" (protecting lives) for the panel, acknowledging that cyberattacks now have physical consequences and affect the delivery of care.  3. Are third-party partnerships the new "Backdoor" into health data?  As healthcare delivery becomes more decentralised, the "perimeter" of the hospital dissolves into the local community. This question for the panel examined the risks inherited from the vast supply chain of vendors, from billing processors to cloud providers.  4. How will AI weaponise and defend the next generation of health data breaches? Artificial Intelligence is a double-edged sword. This question for the panel explored the impending "arms race" between threat actors using AI to exploit systems and defenders using AI to patch them.  5. Is the "Human Firewall" of people failing due to clinical burnout and care complexity?  Technology is only as strong as the people using it. This question for the panel addressed the psychological and ergonomic factors that make healthcare workers uniquely vulnerable to social engineering. Health Tech Forward 2025 in Barcelona Health Tech Forward 2025    Conference Name: Health Tech Forward 2025 Location: Palau de Congressos de Barcelona in Barcelona, Spain. Dates: December 3-4, 2025. Focus: Europe's premier event for health tech innovation and investment, featuring keynote speeches, dynamic panel discussions, and targeted 1:1 networking opportunities. Panel Topic Context: The panel falls under the track/topic of cybersecurity, compliance, and collaboration(often referred to as the "3C's"), addressing the critical security challenges facing the healthcare sector as it adopts new technologies.   The conference agenda often covers themes ranging from AI insights and clinical breakthroughs to consumer tech & wellness.  https://healthtechforward.com >> Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk   Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @   https://www.healthcare.digital     We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb     Founders for Founders >  We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk   #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #BuySide   #SellSide #Divestitures   #Corporate   #Portfolio   #Optimisation   #SeriesA   #SeriesB   #Founders   #SellSide   #TechAssets   #Fundraising #BuildBuyPartner   #GoToMarket   #PharmaTech   #BioTech   #Genomics   #MedTech   Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk   Meet Us @ HealthTech events   October 2025 Healthcare Summit 2025, London, UK – Chairing the HealthTech M&A Panel Healthcare Summit 2025, London, UK – Chairing the HealthTech Deal Structuring Panel NHS Clinical Entrepreneur Conference, Belfast, Northern Ireland Global Health Exhibition 2025, Riyadh, Saudi Arabia – Chairing the HealthTech M&A Panel November 2025 HealthTech X Summit, London, UK – Chairing the “HealthTech predictions for 2026” Panel MedTech Europe 2025, Valletta, Malta- Speaker on the "Startups, Corporates & Hospitals: How to Build Meaningful MedTech Partnerships" panel MedTech Europe 2025, Valletta, Malta- Judge for the MedTech StartUp Pitch Awards Leaders in Health Summit 2025 December 2025 HealthTech Forward 2025, Barcelona, Spain – Moderating the Health Data Under Attack” Panel Healthcare Club, IESE Business School, Barcelona, Spain HealthInvestor Power List Awards 2025, London, UK – Judging Panel Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk

Nelson Advisors invited to Chair the 'Finance in Healthcare’ Panel at the IESE Business School Healthcare Club event Nelson Advisors Partner Lloyd Price was invited to Chair the discussions at the IESE Business School Healthcare Club event on the 3rd December in Barcelona. Lloyd was joined on the panel by Javier Matacàs, Investment Director at Careventures and ⁠Ilan Misano, CEO of X-Applied and former Head of the StartUp Growth Lab - Google Israel's startup accelerator. Panel > Topics and Questions The Panel covered a wide range of themes and questions including: What types of transactions do you advise on? (sell-side, buy-side, carve-outs) What is your firm’s AUM and fund structure (fund size, lifecycle, geography)? Your investment strategy? And how many deals do you typically complete per year? What stages do you invest in? What is your fund thesis and typical ticket size? And How do you support portfolio companies after investing? What is your typical role during a transaction? IESE Business School IESE Business School is the graduate business school of the University of Navarra, with its main campus located in Barcelona, Spain. It is consistently ranked among the top business schools globally, particularly for its MBA and Executive Education programs. Key Characteristics Global Mindset: IESE has a strong international focus with a highly diverse student body and campuses in Barcelona, Madrid, New York, Munich, and São Paulo. Case Method: The school is well-known for its extensive use of the case method, a teaching approach that uses real-world business problems to develop students' critical thinking, problem-solving, and decision-making skills. Values-Based Leadership: IESE emphasises a people centred vision and a commitment to ethics and social responsibility, aiming to educate leaders who can have a positive impact on business and society. Programmes IESE offers a variety of programs, including: Full-time MBA: A 15- or 19-month program known for its global approach. The curriculum includes core courses in the first year and a wide selection of electives in the second. Executive MBA (EMBA): A part-time program designed for experienced professionals. Global Executive MBA (GEMBA): A blended program with on-campus and online components. Executive Education Programs: These are consistently ranked among the best in the world and are aimed at functional managers, senior executives, and C-suite leaders. Rankings and Reputation IESE's programs are highly regarded in international rankings. Recent rankings include: Financial Times Global MBA Ranking: Consistently ranked in the top 10, with a #3 ranking in 2025. The Economist Full-time MBA Ranking: Ranked #1 in the world in 2021. Financial Times Executive Education: Ranked #1 for six consecutive years (2015-2020) and continues to be highly ranked.The school holds triple accreditation from AACSB, AMBA, and EQUIS. https://www.iese.edu IESE Business School > Healthcare Club The IESE Business School Healthcare Club is a professional student club at IESE that focuses on the healthcare industry. Its mission is to support IESE students who are interested in pursuing a career in healthcare by providing them with the resources, knowledge, and networking opportunities they need. The club's activities are designed to help students: Learn about the healthcare sector: They organize seminars, workshops, and panels with industry experts, IESE professors, and alumni. These events cover various aspects of the healthcare industry, from pharmaceuticals and medical devices to digital health and healthcare consulting. Network with industry professionals: The club facilitates connections with leading healthcare companies, startups, and alumni. They host networking events, company visits, and an annual "Healthcare Day" conference, which brings together top professionals to discuss current trends and challenges in the industry. Find a job in the healthcare sector: The club offers career support through CV/cover letter workshops, interview preparation, and a mentorship program that connects students with experienced professionals. They also organise career treks to major healthcare hubs like Basel, Switzerland, and Madrid, Spain, where students can visit companies and network with potential employers. The IESE Healthcare Club plays a key role in positioning the IESE MBA as a source of top talent for healthcare companies and is a valuable resource for students aiming to transition into or advance their careers in this dynamic and impactful industry. https://groups.iese.edu/healthcare/home/ >> Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events October 2025 Healthcare Summit 2025, London, UK – Chairing the HealthTech M&A Panel Healthcare Summit 2025, London, UK – Chairing the HealthTech Deal Structuring Panel NHS Clinical Entrepreneur Conference, Belfast, Northern Ireland Global Health Exhibition 2025, Riyadh, Saudi Arabia – Chairing the HealthTech M&A Panel November 2025 HealthTech X Summit, London, UK – Chairing the “HealthTech predictions for 2026” Panel MedTech Europe 2025, Valletta, Malta- Speaker on the "Startups, Corporates & Hospitals: How to Build Meaningful MedTech Partnerships" panel MedTech Europe 2025, Valletta, Malta- Judge for the MedTech StartUp Pitch Awards Leaders in Health Summit 2025 December 2025 HealthTech Forward 2025, Barcelona, Spain – Moderating the Health Data Under Attack” Panel Healthcare Club, IESE Business School, Barcelona, Spain HealthInvestor Power List Awards 2025, London, UK – Judging Panel Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk